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ABSTRACT
Ginseng is one of the most commonly consumed herbal medicines in the
world. Consumption is highest in females, thus my studies purpose was to define
the concentration responsive effects of North American alcoholic and aqueous
ginseng extracts on preimplantation development in vitro, and on pregnancy and
post-partum development in the mouse. Two-cell embryos from female mice
were cultured with five different concentrations of both extracts, ginsenosides
Rb1, Rg1 and Re, a combinatorial ginsenoside solution and a polysaccharide
fraction. Embryonic development and recovery from treatment was assessed. To
investigate in vivo effects of ginseng extracts, females were gavaged with 50
mg/kg and 500 mg/kg of either extract (treatment), gavaged water (sham) or not
gavaged (control) for two weeks prior to mating and throughout gestation.
Gestation period, litter size and pup growth were evaluated. The results
demonstrate that typical ginseng consumption levels do not adversely affect
fertility or pregnancy in the mouse, however direct exposure to ginseng extract in
vitro is detrimental to preimplantation development.

Key words: mouse, preimplantation development, ginseng, ginsenoside, North
American ginseng, pregnancy, post-partum development, concentrationdependent developmental blockade, gavage, women
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1
Introduction
1.1

Rationale - Overview
Herbal medicinal products are a growing market due to their increased

integration into peoples every day lives. In the United States (US), their
consumption has increased by 380% in the general population between 1990 and
1997 (Eisenberg et al. 1998). Additionally, in 1994 the total US sale of herbal
products was $4 billion (Brevoort 1998). Among these popular herbal remedies is
ginseng, whose consumption and inclusion as part of a healthy diet is on a
dramatic rise due to its many purported health benefits, making it one of the 10
most commonly used herbal medicines in the United States (Bent and Ko 2004).
Ginseng is an herb in the Araliaceae family and is a species in the genus Panax,
which means, “all healing” and “longevity”, and while its medicinal properties
have been appreciated in Asia for over 2000 years, it is now becoming
increasingly important across the world, specifically in North America (Chu et al.
2009).
Research focused on investigating the therapeutic effects of ginseng has
considerably increased due to its ever-growing popularity as an herbal remedy.
Research is required to ensure that human consumption of ginseng is safe and to
define the mechanisms underlying its beneficial effects. Studies have
demonstrated that ginseng extracts are composed of many compounds with
unique and beneficial influences on various body systems, including the
cardiovascular system, nervous system and the reproductive system (Attele et al.
1999). However, as herbal remedies are usually deemed harmless because they
are “natural”, this does not in any way ensure that normal levels of consumption
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of these products are safe (De Smet et al. 2004). In a US survey conducted in
2001, 9.1% of 242 pregnant women questioned declared use of herbal medicinal
products during their current pregnancy, and 7.5% were using these supplements
at least weekly. The most commonly used products were garlic, aloe, chamomile,
peppermint, ginger, Echinacea, pumpkin seed and ginseng (Gibson et al. 2001).
In Asia, up to 10% of women have reported use of ginseng through out their
pregnancy (Chin 1991). With more women of reproductive age taking herbal
supplements, it is important to investigate ginseng’s effect and safety on
preimplantation development and pregnancy.
To date, research investigating ginseng’s impact on reproductive function
has demonstrated a positive effect on sperm motility (Zhang et al. 2006), but also
lower morphological scores for in vitro treated rat and mouse embryos than for
those cultured in a normal environment (Chan et al. 2003, 2004; Liu et al., 2005a,
2005b, 2006). This later outcome is quite controversial since Lee et al. 2008
found that treatment of early rat embryos with individual ginsenosides caused
either no significant change to the morphological scores within the organogenic
parameters used, and in some cases actually improved them. Ginseng may also
protect mouse embryos from oxidative stress due to ethanol-induced
teratogenesis during embryonic organogenesis via activation of embryonic
antioxidant enzyme defense systems (Lee et al. 2009). In addition, very recent in
vivo studies have shown that when administering 20, 200 and 2000 mg/kg/day
(2000 mg/kg/day being ≈200 times the recommended clinical dose) of Korean
Red Ginseng Extract to females for two weeks before mating and through out
gestation, that maternal weight, feeding, embryonic implantation and fetal growth
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were not significantly affected (Shin et al. 2010). While research in this field is
advancing quickly, it is important to establish whether consumption of all ginseng
extracts are safe during pregnancy and what effects, if any, direct exposure to
these extracts may have on preimplantation development. Furthermore, due to so
much variability between the compounds found in different ginseng products
(Liberti and Der Marderosian 1978), it is important to study the effects of different
ginseng species and extracts on reproduction, which is why the aqueous and
alcoholic extracts produced from North American ginseng (NAG) are used in this
research.
Addressing these concerns were the primary purpose of my study. I
investigated the effects of aqueous (AQ) and alcoholic (ALC) NAG extracts and
individual ginsenosides and polysaccharides on preimplantation development in
vitro. I also investigated the influences of both ginseng extracts on fertility,
pregnancy and post-partum development in the mouse. I have applied my studies
to the mouse since it is a well characterized research model for understanding
mammalian development. Furthermore, it is critical to conduct animal model
studies prior to trials applied directly to the human.

1.2

Embryonic Development: From Fertilization to Childbirth

1.2.1 Preimplantation Development
Preimplantation development encompasses the developmental period
from fertilization to embryo implantation into the uterine wall (Watson and Barcroft
2001). Fertilization occurs in the swollen ampulla of the oviduct, also referred to
as the fallopian tube in the human, and includes the fusion of a sperm with a
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mature oocyte released from the ovary. The embryo travels down the oviduct
towards the uterus. The first cleavage division occurs 16-20 hours following
fertilization and is characterized by an asynchronous doubling of the number of
cells, producing a short period of time where cell number may not be even.
Cleavage produces an embryo with two cells of approximately equal size called
blastomeres (Fujimori 2010). The first major developmental transition that occurs
during these early stages of development is the zygotic gene activation, where
the developmental program of the embryo is no longer exclusively directed by
maternal proteins and transcripts, but by newly expressed genes (Schultz 2002).
Individual blastomeres are easily distinguished until half way through the
eight-cell stage in the mouse when compaction, the first morphological event,
transpires. Compaction is characterized by an increase in cell-cell adhesion due
to E-Cadherin and tight junction (TJ) formation, (Shirayoshi et al. 1983; Watson
and Barcroft 2001) causing the membranes of individual blastomeres to be
indiscernible. Compaction is also linked to the onset of cellular polarization of the
outer cells of the embryo, (Watson and Barcroft 2001) which form the
trophectoderm (TE). Additionally, the inner cells give rise to the Inner Cell Mass
(ICM) (Johnson and McConnell 2004). At the 32-cell stage, multiple small fluid
filled cavities begin to form in the embryo due to active transport of ions and
subsequent fluid movement down the ionic concentration gradient across the
trophectoderm epithelium, a phenomenon known as cavitation. The individual
cavities fuse together and create the blastocyst cavity, which separates the two
cells types. The ICM cells are pluripotent and become the embryo proper,
whereas the TE gives rise to the placenta. These final steps lead to the formation
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of the blastocyst, which precedes embryo implantation to the uterine wall and is
the last step of preimplantation development (Enders and Shlafke 1968; Lin et al.
2001; Watson and Barcroft 2001; Fujimori 2010).

1.2.2 Implantation
Implantation is the attachment of the embryo to the maternal endometrial
epithelium and its ensuing invasion into the stroma (Hemberger 2012). The TE,
previously referred to as the outer cell layer of the embryo, is made up of
trophoblast cells, and its initial role is to mediate implantation of the blastocyst
into the uterine wall (Enders and Shlafke 1968). Before invasion by trophoblast
cells begin however, maternal endometrial stromal cells transform into decidual
cells and form a dense cellular matrix called the decidua. This physical barrier
slows embryonic migration toward the mother’s uterine spiral arteries (Kearns
and Lala 1983) and promotes trophoblast attachment rather than invasion
(Kliman 2000). The decidualized stromal cell is also a secretory cell and
expresses new proteins such as prolactin and insulin-like growth factor binding
protein-1 (IGFBP-1) (Tarantino et al. 1992). After decidualization, the trophoblast
cell differentiation pathway is altered, and villous trophoblasts are transformed
into anchoring trophoblasts (Kliman 1994; Kliman 1999) in part due to contact
with the decidua. Trophoblasts then migrate to the uterus and direct their
movement toward the maternal spiral arteries where their cellular extensions form
an anastomosing network around the implantation site. This allows permeation of
the attachment site with maternal blood via low resistance channels. Finally,
trophoblasts limit their invasion to the upper third of the uterus and are eliminated
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after delivery (Strickland and Richards 1992; Cross et al. 1994; Kliman 1994;
Hemberger 2012).
While implantation is extremely complex and not all compounds involved
have been discovered, the function of many proteins and cytokines is known.
Interleukin-1, specifically interleukin-1β (IL-1β), is proposed as one of the factors
mediating cross-communication between the maternal endometrium and the
implanting blastocyst (Simon et al. 1994; Simon et al. 1997). IL-1β also induces
expression of IGFBP-I, which allows dissociation of filamentous actin during
decidualization (Kim et al. 1999) and MMP-3, which degrades several
components of the extracellular matrix and basement membrane thus allowing
decidualization to ensue (Hemberger 2012). Lastly, insulin-like growth factor
(IGF) signaling systems allow cell-cell communication between fetal trophoblasts
and maternal decidual cells by interactions between IGF-II and IGFBP-I,
(Hamilton et al. 1998) which may act synergistically to enhance trophoblast
migration. In conclusion, the fate of implantation is likely due to the balance
between the invasive promoting protease generated by trophoblasts and the
inhibitors of invasion created by the decidua (Feinberg et al. 1989; Graham and
Lala 1991; Strickland and Richards 1992; Kliman 1994).

1.2.3 Embryogenesis
Embryogenesis is the progression of events adhered to by the embryo in
order to form and develop into a healthy baby. Initially, the TE gives rise to the
chorion, the precursor of the placenta. The ICM contributes to the embryo proper
and gives rise to the yolk sac, allantois and amnion. Following implantation, the
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embryoblast forms a bilaminar embryonic disc called the embryonic epiblast,
which provides most of the cells contributing to the embryo proper (Hall 1999,
2000). Afterward, gastrulation occurs, where two germ layers are generated from
the single layered blastula, the inner ectoderm and outer endoderm. The
mesoderm, the third and middle germ layer, forms secondly (Hall 1999, 2000).
Each germ layer differentiates into different organs and tissues in the body. The
ectoderm becomes the epidermis of the skin and the neural tissue. It also
differentiates into numerous crucial reproductive organs such as the mammary
glands, the hypothalamus, both pituitary lobes, the caudal vagina, the vestibule,
the penis and the clitoris (Gilbert 2000). The endoderm forms the lining of the
gastrointestinal and respiratory tract as well as their derivatives. Finally, the
mesoderm differentiates into the urogenital, circulatory and supportive muscular
system as well as the female and male gonads, the uterus, the cervix, the cranial
vagina, the epididymis and the accessory glands (Senger 2003; McGeady et al.
2006). Additionally, a fourth germ layer arises during primary neurulation called
the neural crest (Hall 1999, 2000). Once all germ layers have been established,
organogenesis begins. Organogenesis is the process through which individual
germ layers develop into the internal organs of the body, and is initiated by
secondary neurulation and the formation of the neural tube. Also, blastema cells
(cells capable of growing and regenerating into bodily tissues and organs)
differentiate into the hindgut, blood vessels, somites, trunk neural crest cells, and
the notochord (Hall 1998; O’Rahilly and Müller 1999). At this point, organ
development continues and includes formation of the central nervous system, the
epidermis, cutaneous structures, the skeletal and muscular system, the heart,
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blood vessels and cells, the respiratory and gastrointestinal tract, sex organs and
all other systems in the body (Gilbert 2000).

1.2.4 Placentation
Placentation is the formation and arrangement of the placenta. In the
mammal, as formerly described, the placenta is derived from the trophoblast cells
of the TE (Johnson and McConnell 2004). Immediately after implantation, TE
cells that are not in direct contact with the ICM differentiate into highly polyploid
trophoblast giant cells that line the entire implantation site (Sutherland 2003;
Hemberger 2012). These cells, along with a juxtaposed layer of endodermal
cells, form the parietal yolk sac, (Chazaud et al. 2006) which mediates nutrient,
gas, and waste exchange between the mother and embryo before the mature
placenta takes over on embryonic day 9.5-10.5 (Hemberger 2012). Furthermore,
the parietal trophoblast giant cells protect the embryo through a microbial
defense system and shield the embryo from immune rejection by the mother
(Amarante-Paffaro et al. 2004). Contrastingly, the TE cells that are in contact with
the ICM continue to proliferate, give rise to extra-embryonic ectoderm (ExE) cells,
and migrate into the ectoplacental cone (EPC) (Hemberger 2012). At this stage,
the peripheral cells cease to proliferate. They become larger and less congested
and differentiate into a secondary population of trophoblast giant cells (Parast et
al. 2001; Sutherland 2003). This proliferative zone is necessary to provide a
sufficient number of cells to form the future placenta.
In the mouse, the placenta forms around mid-gestation into three layers:
the maternal decidua, the junctional zone and the labyrinth (Hemberger 2012).
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The functions most attributed to the placenta are nutrient and gas exchange,
which are accredited to the labyrinth in the mouse, and the chorionic villi in the
human (Rossant and Cross 2001). This layer is formed by fusion of the allantois
and the chorion, and branches out at defined initiation sites to establish an
intricate fetal vascular network. This network ensures that the maternal and fetal
blood circulation come into very close contact, but never intermingle, ensuring
continued fetal growth (Hemberger 2012).

1.2.5 Parturition
Parturition is the step-by-step process of giving birth, and is the last stage
in fetal development. There are five independent physiological actions that
constitute parturition: fetal membrane rupture, cervical dilatation, myometrial
contractility, placental separation and finally uterine involution (Olson et al. 1995).
These events result in the birth of the baby and the restoration of a regular
cyclical uterine physiology. The process by which parturition is initiated has been
extensively investigated. Pregnancy is characterized by long-duration and lowamplitude contractions in the myometrium, whereas contractions become shorter,
high amplitude and synchronous throughout the entire muscle during active labor
(Taylor et al. 1983). Uterine quiescence is a state maintained throughout
pregnancy, and is controlled by high concentrations of progesterone. When
progesterone quantities are elevated, the myometrium does not contract when
stimulated by oxytocin or PGF2α (Challis and Olsen 1988). However, the
dormancy state is lost during childbirth, and labor initiation is suggestively
controlled by a reduction in the concentration of circulating progesterone (Csapo
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1956). Uterine activation and stimulation are considered two separate but parallel
physiological events (Lye and Challis 1989). To begin, uterine activation is
considered to be the result of a relative surge of estrogen at term in the face of a
high progesterone environment (Albrecht and Pepe 1990; Olsen et al. 1995).
Activation incorporates many modifications in myometrial cells, such as resting
membrane potential changes, augmented levels of myosin and actin, elevated
gap junction, oxytocin and prostaglandin (PG) receptor expression and finally an
increase of post-receptor coupling mechanisms (Olsen et al. 1995). Interestingly,
PGs have been shown to have a role in uterine activation by stimulating the
formation of gap junctions in rat myometrium (Garfield et al. 1980). Secondly,
uterine contractile stimulation is linked to increasing myometrial responsiveness
to oxytocin in late gestation (Nathanielsz and Honnebier 1992; Hirst et al. 1993).
Hirst et al. 1991 discovered that the intensity and duration of contractions
amplified in parallel with growing levels of oxytocin in rhesus monkey plasma.
While oxytocin is not responsible for the onset and timing of labor, it contributes
to the expulsive phase of parturition. Moreover, PGs are also essential in
maintenance of labor, and like oxytocin, their levels rise after labour has started
and through out its progression. Lastly, hormones initiating, activating and
stimulating parturition may be coordinated in part by an intrauterine
communication system composed of steroids, cytokines and PGs (Keirse 1990;
Olsen et al. 1995). While research is quickly advancing, the process of parturition
is complex and inadequately understood, requiring additional studies before a
complete understanding of the mechanisms controlling labor are effectively
known.
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1.3

Herbal Medicines and Pregnancy
Intriguingly, most survey data indicate that women are the predominant

users of herbal medicines (MacLennan et al. 1996; Eisenberg et al. 1998; Ernst
and White 2000), and as previously indicated, 9.1% of pregnant women take
herbal supplements through out their pregnancy (Chin 2001). The most alarming
fact surrounding these statistics however, is the lack of accessible resources and
information regarding the safety of consuming herbal supplements during
pregnancy. While information may be preliminary, herbs have been associated
with possible health risks through out child bearing (Ernst 2002).
The definition of a word helps people understand its significance and
importance. Due to the fact that herbal remedies are characterized as
“supplements” and are deemed “natural”, consumers often believe that they are
inherently safe and do not have similar properties to drugs that can have
biological and clinical effects when ingested. This of course is a false assumption.
The general population needs to be careful when contemplating herbal remedies
(Stein 2002). In many countries, including the United States, natural products are
not rigorously regulated, and people may not necessarily know what they are
consuming (De Smet et al. 2004). It is clear that these products can have clinical
effects on the body, however because they are not classified as drugs, they do
not require approval or rigorous testing by the FDA before they are put on the
market (Stein 2002). Furthermore, the only way the FDA is empowered to
remove herbal remedies from the consumer’s reach is if they are proven unsafe
rather than initially being proven safe by the manufacturer (Goldman 2001).
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Undeniable characteristics of herbal remedies mark them and their potential
therapeutic effects as unpredictable, as follows:
Phytochemical studies have indicated that the concentration of the
principal compounds present in several herbal supplements on the market, such
as St. John’s wart, ginko, Echinacea, soy and ginseng, vary dramatically from
product to product (De Smet et al. 2004). For example, hypericin is a bioactive
compound found in St. John’s Wart. On the label of different products found at a
local health food store, it was stated that levels of 0.3% hypericin differed for
many products and ranged between 180mg and 530mg. Other labels listed
hypericin but did not include the concentration or amount of active ingredient in
the product or simply stated that parts of the plant were used but not the specific
compounds found in them. Finally, while some labels did indicate an awareness
of certain studies performed on hyperforin, others indicated that no barriers exist
to selling herbal remedies of uncertain potency and safety (Goldman 2001).
Unfortunately, there are many limitations to our understanding of all the active
compounds found in herbal products, and setting a standard for each of them
individually would be extremely challenging if not near impossible.
Chemical analysis is no longer valuable when the ingredients responsible
for a plant’s activity are unknown and have not been identified. On another note,
even if these compounds are identified, it is difficult to assess if the crude herb
would be preferable to ingesting the purified active compound (Goldman 2001).
While a method of standardization for compounds found in herbal products would
be indispensable for their quality and safety, any guidelines put into place would
be futile without complete adherence of future regulations by the manufacturers
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as well as supervision at the retail level. In a Canadian study conducted by Mills
et al. 2003, simulated customers visited 33 health food stores one month after
Health Canada published a warning about the hepatotoxic potential of kava. It
was found that 67% of these stores were still selling kava. When the Canadian
ban on kava was made official and 30 stores were revisited two months later, it
was shown that 57% were still selling the dangerous supplement.
Many herbal supplements produce undesirable effects in the body such as
headaches, vaginal spotting, and gastrointestinal discomfort (De Smet et al.
2004). As previously stated, these products are often believed by the public to be
safe due to their natural and organic origins (De Smet et al. 2004). Largely due to
this misconception, half of the herbs taken by patients are not reported to their
physicians, thus a correlation between consumption of natural health
supplements and some of the adverse effects experienced are not commonly
understood (Foster et al. 2000). Furthermore, although no reliable figures about
underreporting of herbal adverse outcomes are available, it has been suggested
that less than 1% of undesirable incidences associated with herbal remedies are
reported to the FDA in the United States (Marcus and Grollman 2002). This
implies that most of the information regarding the harmful effects produced by
these products is not available to the general population, which prevents the
public from making educated choices when deciding to incorporate herbal
supplements into their diets. An additional serious factor when considering the
consumption of herbal supplements is the likely presence of contaminants and
adulterants such as high levels of pesticides, fumigation agents, pathogens,
microbial toxins or toxic botanicals (De Smet et al. 2004). Particularly concerning
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is the presence of toxic levels of heavy metals such as mercury, lead and arsenic
in several Asian medicines purchased in Asian health food stores in the USA,
even when taking the suggested dose found on the package (Garvey et al. 2001).
These adulterants are rarely listed on labels, which make them especially
dangerous. In a California study of Asian medicines purchased from herbal
stores, 32% of a 260 product sample contained undeclared pharmaceuticals or
heavy metals, and 23 had more than one adulterant (Ko 1998). Among the
contaminants found in some Asian herbal remedies are also synthetic
pharmaceuticals such as antihistamines, aromatics, steroids and alkaloids
(Joubert and Mathibe 1989; Gorey et al. 1992; Chen et al. 1993).
Unknown additives in health products are a cause for concern, and the
industry clearly states that not all compounds and chemicals present in
supplements are known or advertised. This indicates that the public must
approach the ingestion of herbal products with great caution, not only for
personal knowledge and safety but also due to possible dangerous
consequences, such as drug interactions. To illustrate, in a group of normal
volunteers being administered St. John’s wort for 10 days, it was revealed that
the herbal product reduced absorption of the drug digoxin by an average of 25%
(Johne et al. 1999). Furthermore, case reports also indicated a significant
increase in the metabolism of other drugs when ingesting St. John’s wort,
including cyclosporine (Ruschitzka et al. 2000), warfarin (Yue et al. 2000), and
oral contraceptives (Ernst 1999). While many people have readily welcomed the
opportunity to gain access to natural remedies claiming to deliver solutions to
some of their health concerns, it may not be so simple due to the lack of reliable
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information provided about these products (Goldman 2001).

1.4

Properties of Ginseng and Ginsenosides
Ginseng is an herbal supplement with a complex chemical composition.

Established compounds are extensive and include polysaccharides (PS),
peptides, polyacetylenic acids, saponins, fatty acids and ginsenosides (Lee
1992). It is suggested that these different composites differ depending on the
species, root age, cultivation time and the method of production (Liberti and Der
Marderosian 1978). Due to production method variation, it is clear that steamed
ginseng products have greater pharmacological potency than non-steamed
ginseng as well as differing bioactive components (Yun 2003). For instance,
using heat (Kim et al. 2000) or sonication (Fuzzati et al. 2000) increases
ginsenoside recovery and biological activity. Specific ginsenosides and their
concentrations will also differ when looking at distinctive ginseng products. For
example, 25 ginseng products purchased from health food stores were tested for
product-to-product variability in ginsenoside concentration. It was found that
ginsenoside quantities varied 15-fold (0.288-4.255% by weight) in the powders
and capsules per 100g of product, and 36-fold (0.361-12.993 g/L) in the liquid
extracts for 100mL of product (Harkey et al. 2001). Finally, the unique chemical
structure of each individual ginsenoside along with the different combination of
compounds found in each specific species are what produce different
pharmacological and physiological effects in the body (Sievenpiper et al. 2003)
such as antioxidant, anti-inflammatory and anti-carcinogenesis benefits
(Wargovich 2001; Kang et al. 2007; Lee et al. 2009;). The ginsenosides are the
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principal bioactive constituents of interest for understanding ginseng medicinal
effects. Approximately 40 ginsenoside compounds have been identified from the
ginseng root and their separation and analysis methods have been extensively
reviewed (Fuzzati 2004).
The most common types of ginseng are American ginseng (Panax
quinquefolium L.) and Asian ginseng (Panax ginseng C. A. Meyer) (Lü et al.
2009). North American ginseng (NAG) has a similar ginsenoside profile to Asian
ginseng. Some marked differences however include a much higher concentration
of ginsenosides Rb1 and Re in the root of NAG, and little to no Rf (Hu and Kitts
2001). In addition, Dr. Edmund Lui at the University of Western Ontario has
determined that the ALC extract derived from NAG possesses twice the total
concentration of ginsenosides as the AQ extract, specifically 282.5 mg/g versus
138.7 mg/g. It was also found that the ALC extract has more Rb1 and Re, but a
lower concentration of Rg1 than the AQ extract. In addition, the major difference
between both extracts is that the AQ extract is composed of 15%
polysaccharides, whereas the ALC extract has none. Ginsenosides belong to a
family of steroids called triterpene saponins and have a four-ring, steroid like
structure with sugar moieties attached. Sugar moieties include but are not
restricted to glucose, maltose, fructose and saccharose and are attached to C-3,
C-6 and C-20 of the chemical structure (Attele et al. 1999). Each one also has at
least two or three hydroxyl groups and depending on their aglycone are either
derivatives of the (20S)-protopanaxadiols (PD), (20S)-protopanaxatriols (PT),
(Tawab et al. 2010) acotillol-type or oleanolic acid groups (Fuzzati 2004).

17
Figure 1.1

Chemical Structures of Main Ginsenosides and their Key

Degradation Products.
Chemical structure and m/z values of main ginsenosides in the
protopanaxadiol and protopanaxatriol groups, as well as their key degradation
products. Also, major fragment ions detected in the initial fragmentation step
(MS2).
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Ginsenoside Structural Diversity

Tawab, M. A., U. Bahr, et al. (2003) Degradation of ginsenosides in humans after oral
administration. Drug Metabolism and Disposition. 31: 1065-1071
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1.5

Pharmacokinetics of Ginseng
The precise plasma level of ginseng and intact ginsenosides in the human

body after daily ginseng consumption is undetermined, as well as whether
absorption of intact ginsenosides by the human gastrointestinal tract is possible
(Tawab et al. 2003). It is now clear that PDs such as Rb1 are converted to
compound-K by enzymes from intestinal bacteria (B-D-glucosidase) through step
wise cleavage of the sugar moieties, (Hasegawa et al. 1996) and PTs such as Re
and Rg1 are hydrolyzed into ginsenoside Rh1 and Rf1 under mild acidic
conditions (Han et al. 1982). This results in a small percentage of intact
ginsenosides being absorbed by the gastrointestinal tract after oral administration
in humans and animals. While many have attempted to discover these
ginsenoside levels, results often vary. The individual amount of each identified
ginsenoside and their metabolites in plasma are not known, however, it was
found that the maximum concentrations of ginsenosides R1, Rg1, Rd, Re and
Rb1 in rat plasma after an oral administration of 10 and 300mg/kg of ginseng
powder were between 1.51 to 6.42 ug/ml on average when samples were taken
regularly over four days (Li et al. 2007a). Additionally, their absolute
bioavailability was 9.29%, 6.06%, 2.36%, 7.06% and 1.18% respectively (Li et al.
2007b). Levels of Rb1 and Rg1 in the plasma have also been determined for
pregnant female mice on gestational day 18 by Shin et al. 2010. Standard
solutions were made and 10, 100, 500, 1,000, and 2,000 µg of ginsenoside Rb1
and Rg1 were dissolved in methanol, filtered and 20ul of each solution was
analyzed by HPLC. It was found that their concentrations in Korean Red Ginseng
Extract are 0.61±0.12% and 0.9±0.17% respectively. However in this case, while
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Rb1, Rg1 and Re were detected after spiking in normal serum, no trace of these
ginsenosides were found in plasma following treatment with the highest dose of
2000mg/kg/day after 30 min and 2h. It was suggested that these ginsenosides do
not reach a detectable blood level by oral treatment due to low absorption in the
gastrointestinal tract.
In the human, Cui et al. 1997 demonstrated that ginsenosides are present
in urine after oral consumption. They demonstrated that 1.2% of a three mg dose
of orally ingested protopanaxatiol ginsenosides and 0.2% of a seven mg dose of
orally ingested protopanaxadiols were recovered in the urine over five days. Yet,
neither the ginsenoside nor its metabolite could be identified, simply the
aglycone. Ginsenosides Rg1, Rd, Re, Rb2 and Rc are more easily detected in
urine than in plasma, which may be attributed to the lower limit of detection
present in urine and indicates that their concentrations in plasma must be
extremely low. It has been documented that even though low levels of intact
ginsenosides are found in mouse plasma, that only ginsenoside Rb1 was
detectable in human blood, and by only one subject (Tawab et al. 2003). This is
due to the fact that only hydrolyzed and metabolized compounds are able to
reach the systemic circulation. The only degradation products to reach circulation
were Rh1 and Rf1 derived from PTs and compound-K originated from PDs
digested in the intestine (Tawab et al. 2003). With the exception of Rb1, it was
established that high levels of intact ginsenosides are not able to reach the
plasma because they are first metabolized. Additionally, while it has been
discovered that low ginsenoside accumulation and bioavailability are due to
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decomposition in the stomach, metabolism in the intestine and elimination in the
liver, it is believed that low membrane permeability is the dominant factor (Han
and Fang 2006). These results indicate that ginsenoside pharmacokinetics are
incredibility variable from one study to another and from one species to another.
Thus pharmacokinetics of ginseng extracts and placental transfer of ginsenosides
in humans must be investigated further.

1.6

Beneficial Effects of Ginseng and Ginsenosides
The scientific literature supports that ginsenosides are responsible for

most of ginseng’s medicinal activities; however non-ginsenoside compounds also
exert certain pharmacological effects, indicating that the whole root can offer
therapeutic advantages (Lü et al. 2009). Ginseng is one of the more frequently
purchased herbs in the US and has been used as an herbal supplement for
hundreds of years by people wanting to boost energy levels, reduce stress and
possibly increase lifespan by maintaining a healthy lifestyle (Angelova et al.
2008). People with certain illnesses also use ginseng. For instance, patients with
cardiovascular disease and HIV use this herbal remedy in conjunction with their
treatments. A Canadian survey conducted in 2003 found that 6% of patients with
cardiac illnesses reported use of ginseng (Wood et al. 2003). Interestingly,
ginseng is also used by 34% of HIV positive patients on antiretroviral therapy
making it the 10th most used complementary and alternative medicine (Standish
et al. 2001). Due to the overall activity and complexity of the herb, its use to
target benefit to a wide number of the various systems of the body is not
surprising.
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1.6.1 Reduction of Blood Glucose and Improvement of Diabetes
Diabetes is a major global health problem affecting about 3% of the world
population (Park et al. 2005). Of this 3% worldwide, over 90% of diabetic patients
have type two diabetes, which is mostly related to aging, diet and lifestyle. It can
cause serious health complications and can reduce life expectancy by 8-10 years
(Astrup and Finer 2000). Fortunately, it has been observed that the root of Panax
ginseng can be used to improve glucose homeostasis and insulin sensitivity
(Sonnenborn and Proppert 1990). Genetically obese diabetic mice treated with a
single 90mg/kg dose of ginseng root extract by intraperitoneal injection had
significantly lower glucose blood levels (Kimura et al. 1999). Furthermore, when
type two diabetic patients and non-diabetic patients were administered three g of
American ginseng root 40 minutes before a test meal, it was demonstrated that
blood glucose levels were lowered in both patient groups (Vuksan et al. 2000).
Ginseng therapy for type two diabetic patients has been shown to significantly
lower blood sugar levels, but it additionally reduces fasting blood glucose and
body weight, elevates mood and improves psychophysical performance (Park et
al., 2005). These observations signify that ginseng may not only be beneficial for
type two diabetic patients, but also more surprisingly for the non-diabetic
population as a preventative measure against developing diabetes in the future.

1.6.2 Antihypertensive Effects
High blood pressure (BP) is associated with many life threatening
diseases and is correlated with an augmented risk of stroke, coronary heart
disease and end-organ illnesses such as renal failure (Park et al. 2005).
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Intracellular Ca2+ availability regulates blood vessel smooth muscle tone and is
strongly influenced by cellular membrane and sarcoplasmic reticulum interaction
in the muscle. In order to establish the effectiveness of a particular drug on high
BP, its influence on the smooth muscle can be analyzed (Lee 1980). It was
discovered that protopanaxadiols (PD) and protopanaxatriols (PT) inhibit Ca2+
binding to the cellular membrane, and that PT ginsenosides were approximately
180% more effective (Lee 1980). Ginseng consumption is thus linked with
normalizing the BP of hypertensive patients (Yammamoto 1992). Additionally,
ginsenosides also lower BP in a dose dependent manner in rats administered
doses of 10-100mg/kg by mediating the release of endothelium-derived nitric
oxide (NO). NO increases the accumulation of cGMP and in turn relaxes blood
vessels (Kim et al. 1994).
Ginseng is also a potent antiplatelet agent (Teng et al. 1989). Endothelial
cell damage is the first step in the genesis of thrombosis and arteriosclerosis,
common precursors of cardiovascular disease. Platelet hyperfunction and
aggregation is associated with an overproduction of Thromboxane A2, which
occurs in patients with cardiovascular thrombotic disease (Park et al. 2005).
Panaxynol is the principal compound in ginseng that exhibits antiplatelet effects
by preventing thromboxane production (Teng et al. 1989). It was also revealed
that panaxynol inhibits aggregation, and thromboxane release and formation in
rabbit platelets, whereas ginsenosides Ro, Rg1 and Rg1 blocked release only
(Kuo et al. 1990). These results certainly suggest that ginseng may have a
therapeutic role in offsetting or even treating various cardiovascular diseases.
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1.6.3 Antioxidant Effects
Ginseng has demonstrated protective effects in the body attributed to its
antioxidant activities. It has been reveled that at concentrations between 50100ug/ml, ginseng can act as a free radical scavenger or hydrogen donor.
Phenolic contents and MRP levels (Kang et al. 2007) or ginsenosides have been
suggested as the active compounds responsible for this observed phenomenon
(Hu and Kitts 2001). Administration of American ginseng was shown to improve
antioxidant enzyme activity in rats for enzymes such as superoxide dismutase
and glutathione peroxidase (Fu and Ji 2003). American ginseng has also been
proven to have a protective effect against free radical damage on myocardial
cells induced by xanthine by countering the action of free radicals (Zhong and
Jiang 1997). Moreover, ginsenoside Re has been revealed to exert antioxidant
properties in cardiomyocytes (Xie et al. 2006) and neuroprotective influences on
cellular damages stimulated by amyloid and serum free medium (Ji et al. 2006).
Additionally, it has been confirmed that ginsenoside Rd can improve astrocyte
differentiation from neural stem cells (Shi et al. 2005). By increasing antioxidant
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enzyme levels and acting as a free-radical scavenger, ginseng and ginsenosides
display protective antioxidant effects on several systems in the body.

1.6.4 The Central Nervous System
Ginseng can wield both stimulatory and inhibitory outcomes on the central
nervous system (Saito et al. 1977), and may have a regulatory role on
neurotransmission. Ginsenosides Rb1 (Benishin et al. 1992), Rg1 (Yamaguchi et
al. 1995) and Re (Yamaguchi et al. 1996) have preventative effects against
scopolamine-induced memory deficits. Central cholinergic systems are involved
in mediating learning and memory processes (Perry 1986). It was disclosed that
Rb1 could partially reverse scopolamine-induced amnesia by increasing
cholinergic activity (Takemoto et al. 1984; Salim et al. 1997) via augmented
uptake of choline in cholinergic nerve endings (Benishin 1992) and aiding in the
release of acetylcholine from hippocampal slices (Benishin 1992). These studies
signify that ginsenosides may improve memory, facilitate learning and effectively
enhance nerve growth (Takemoto et al. 1984; Salim et al. 1997). On another
note, ginsenosides can protect neurons from ischemic damage. It was revealed
that Rb1 rescued hippocampal neurons from fatal ischemic damage (Lim et al.
1997) and was able to delay neuronal death from transient forebrain ischemia
(Wen et al. 1996). Finally, ginseng extract is also associated in nerve
transmission modulation by decreasing neurotransmitter availability. It was
demonstrated that ginseng can impede uptake of GABA, glutamate, dopamine,
noradrenalin and serotonin in rat brain synaptosomes (Tsang et al. 1985) and
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that individual ginsenosides compete with agonists for binding to receptors
GABAa and GABAb (Kimura et al. 1994).

1.6.5 Anticancer Activities
While advances in cancer therapies such as radiotherapy, chemotherapy and
surgical removal are steadily improving treatment and cancer survival rates,
cancer patients are increasingly turning to natural products for assistance in
treating their disease, which has stimulated research investigating the chemopreventive effects of natural compounds (Park et al. 2005). Ginseng is a very
effective anti-carcinogenic agent in various different ways. To begin, ginsenoside
Rh2 inhibits the growth and colony forming ability of Morris hepatoma cells, thus
transforming the cells characteristics back to those resembling normal liver cells
both functionally and morphologically (Odashima et al. 1989). Rh2 and Rg3 also
prevent prostate cancer cell proliferation (Kim et al. 2004). Specific ginsenosides
also have anti-metastatic effects. Most cancer patients do not succumb to
primary tumors but to metastases, which are tumor colonies that detach
themselves and travel to distant regions of the body (Friedberg 1986). Rg3 was
reported to restrict lung metastasis of tumor cells by preventing invasion and
adhesion of these cells, as well as having anti-angiogenic properties (Mochizuki
et al. 1995). Rb2 can inhibit invasion to the basement membrane by suppressing
MMP-2 in some endometrial cancers and has been used as a medication to
reduce secondary spreading of uterine endometrial cancers (Fujimoto et al.
2001). As demonstrated, ginseng has been thoroughly investigated and its
preventative effects against carcinogenesis are extensive.
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Administration of Korean red ginseng greatly reduced the incidence and
proliferation of tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA),
urethane and aflatoxin B1 (Yun et al. 1983). Furthermore, Korean ginseng was
characterized as a non-organ specific agent with protective effects against cancer
mostly due to ginsenosides Rg3, Rg5 and Rh2 (Yun 2003). It also suppressed
liver (Wu et al. 2001) and colon carcinogenesis through inhibition of cell
proliferation (Fukushima et al. 2001). On another note, American ginseng plays a
protective role against breast cancer (Duda et al. 2001) and is often taken along
with breast cancer therapies due to their synergistic capabilities of suppressing
breast cancer cell growth (Duda et al. 1999). Finally, orally administered
ginsenoside Rh2 is associated with tumor growth retardation in human ovarian
cancer cells (HRA) (Tode et al. 1993) and apoptosis induction in tumors. Rh2
increases natural killer activity in spleen cells of tumor-bearing nude mice
(Nakata et al. 1998). Thus apoptosis, inhibition of cell growth and invasion, and
tumor proliferation reduction seem to be some of ginseng’s many anticarcinogenic mechanisms.

1.7

Effects of Ginseng on the Reproductive System
Research to date has indicated that ginseng’s effects on the body can be

either beneficial or harmful, and its influences on the reproductive system are no
exception. For example, Ginsenoside Rh2 action is associated with tumor growth
retardation and apoptosis induction in ovarian cancer cells (Tode et al. 1993).
Also, Ginseng may protect mouse embryos from oxidative stress via activation of
embryonic antioxidant enzyme defense systems (Lee et al. 2009). In regards to

28
fertility, ginsenoside Re significantly enhances both fertile and infertile sperm
motility in a concentration dependent manner (Zhang et al. 2006). Furthermore,
Lee et al. 2008 demonstrated that treatment of early rat embryos with individual
ginsenosides caused either no change in their morphological score, or improved
them when compared to those cultured in a normal environment. Conflictingly, it
was determined that similar treatment with individual ginsenosides actually
lowered morphological scores for in vitro treated rat and mouse embryos (Chan
et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006), which could be potentially
hazardous for embryonic and fetal development. On another note, very recent in
vivo studies have demonstrated that when administering Korean Red Ginseng
extract to females for two weeks before mating and through out gestation, that
maternal weight, feeding, embryonic implantation and fetal growth were not
significantly affected (Shin et al. 2010). Thus the potential for ginseng to affect
the reproductive system is significant and must to be considered when deciding
to incorporate ginseng as part of a healthy lifestyle. Additionally, with more
people taking herbal supplements (Eisenberg et al. 1998) and the majority being
women (MacLennan et al. 1996; Eisenberg et al. 1998; Ernst and White 2000),
understanding ginseng’s effect on fertility, pregnancy and post-partum
development is of utmost importance for future reproductive health. To date, no
studies have investigated the effects of North American Ginseng extracts on
reproductive function, and my study is focused on providing essential data related
to the safety of ginseng consumption on early development in vitro and
pregnancy and postpartum development in the mouse.

29

1.8

Hypothesis and Objectives
The principal hypothesis of this study is that aqueous and alcoholic

ginseng treatment will promote preimplantation development, pregnancy and
post-partum development in the mouse.
This study has addressed the following objectives to test my principal
hypothesis:
1) Investigate the concentration response effect of aqueous and alcohol
ginseng extracts, specific ginsenosides and polysaccharides on mouse
preimplantation development in vitro.
2) Investigate the combinatorial effect of ginsenosides Rb1, Rg1 and Re on
mouse preimplantation development in vitro.
3) Investigate the safety of consuming both ginseng extracts on fertility,
pregnancy and post-partum development in the mouse.
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Methods and Materials

2.1

Objective One

Investigate the concentration response effect of aqueous and alcoholic ginseng
extracts, specific ginsenosides and polysaccharides on mouse preimplantation
development.

Chemicals
KSOMaa (potassium simplex optimized medium with amino acids) was used for
embryo culture medium (Chemicon, Temecula, CA, USA). The Ontario Ginseng
Growers Association provided four-year-old North American ginseng roots, which
were shipped to Naturex (USA) for extraction. To begin, four kg of the ginseng
root was ground to ½ and ¼ inch, and used to produce the AQ and ALC extract.
The ground roots were soaked three times for five hours in 16 L of either water or
ethanol/water (75/25, v/v) solution at 40°C. The solution was then extracted and
filtered, and the excess solvent was removed by rotary evaporator under vacuum
at 45°C. The three pools were combined and concentrated until the total dry
solids were around 60%. Finally these concentrates were lyophilized at -50°C
(Labconco, USA) under reduced pressure to produce either the AQ or ALC
extracts. Yield of the powder extracts from the concentrates was about 66%.
Final yields for the aqueous and alcoholic extract (mean ± standard deviation of
% extractive) were 41.74 ± 4.92 and 35.30 ± 5.01 respectively. The lyophilized
ALC, AQ ginseng extracts and polysaccharide fraction were obtained from Dr.
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Edmund Lui and prepared in accordance with Azike et al., 2011. Ginsenosides
Rb1, Rg1 and Re were purchased from Sigma (St Louis Mo. USA).

Animals
All animal care and handling procedures were conducted as approved by the
University of Western Ontario, Animal Care and Veterinary Science (ACVS),
standard operating procedures, that conform to guidelines produced by the
Canadian Council for Animal Care (CCAC). Six-eight week old female MFI mice
were purchased from Harlan Sciences, (Indiana, USA) and CD1 mice were
purchased from Charles River (Canada). Each female was injected with 0.1 ml
PMSG, then 0.1 ml hCG 48 h later and placed with CD1 males for mating.
Pregnancy was confirmed the following morning by the presence of a vaginal
plug which was considered gestational day one. On gestational day two, the mice
were euthanized employing CO2 asphyxiation, followed by cervical dislocation as
outlined in Western University ACVS standard operating procedures. Mice were
then dissected and oviducts were removed and flushed with M2 flushing medium
(Sigma, St Louis, MO, USA) to collect two-cell stage zygotes for experimental
purposes.

Experimental Groups
Alcohol and Aqueous Ginseng Extracts
The two-cell embryos were washed three consecutive times in KSOMaa. Then
0.01 g of the alcoholic and aqueous ginseng extracts were individually mixed with
1 mL KSOMaa to prepare two individual 10 000 µg/ml stock solutions. These
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stock solutions were then used to make five different concentrations of each
extract: 0 (control), 10, 50, 250 and 1000 µg/ml. In all groups, 20 embryos were
cultured in 20 µl drops under oil. All treatment groups were then put into culture at
37°C under a 5% O2, 5% CO2 and 90% N2 atmosphere for 48 h.

Ginsenoside Rb1, Rg1 and, Re
Five groups were established for Rb1, Rg1, and Re. Ginsenoside concentrations
were calculated to equal the actual individual concentrations in the aqueous and
alcoholic extracts. 1 mg of ginsenoside Rb1, Rg1 and Re were individually mixed
with 1 mL KSOMaa to prepare three -1000 µg/ml stock solutions. The stock
solutions were then used to make five different concentrations for each individual
ginsenoside equal to the AQ extract: Rb1 was 66.2, 16.6, 3.3, 0.7 and 0 µg/ml;
Rg1 was 13.1, 2.6, 0.66, 0.15 and 0 µg/ml; Re was 55.9, 14.0, 2.8, 0.6 and 0
µg/ml, and five different concentrations for each individual ginsenoside equal to
the alcoholic extract: Rb1 was 164.5, 41.1, 8.2, 1.6 and 0 µg/ml; Rg1 was 2.66,
0.66, 0.15, 0.03 and 0 µg/ml; Re was 89.6, 22.4, 4.5, 0.9 and 0 µg/ml. In all
groups, 20 embryos were cultured in 20 µl drops under oil. All treatment groups
were then put into culture at 37°C under a 5% O2, 5% CO2 and 90% N2
atmosphere for 48 h.

Polysaccharide Fraction
For all experiments conducted with the polysaccharide fraction, CD1 females
were used. Five different groups were established for treatment with the
polysaccharide fraction (PSF). 15% of the aqueous extract is composed of PS,
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thus this percentage was used in order to calculate the five concentrations used.
The highest concentration of the aqueous extract is 1000 µg/ml, which translates
into 150 µg/ml PS present in this solution at the highest concentration. 0.01 g of
the PSF was mixed with 1 mL KSOMaa to prepare a 10 000 µg/ml stock solution.
The stock solution was then used to make the following concentrations: 150,
37.5, 7.5, 1.5 and 0 µg/ml. In all groups, 20 embryos were cultured in 20 µl drops
under oil. All treatment groups were then put into culture at 37°C under a 5% O2,
5% CO2 and 90% N2 atmosphere for 48h.

Morphological Assessment
Embryo development was assessed after 48 h of treatment. After treatment and
culture, the cell number of each embryo was determined and it was categorized
into 2, 4 or 8 cells, 8-cell compacted, morula or blastocyst groups. Micrographs of
the five groups were taken and the cultures were returned to the incubator.

Recovery from Treatment
After the morphological assessment following 48 h of treatment, embryos were
washed three consecutive times in KSOMaa and returned to culture in clean
drops of culture media for another 72 h in order to determine if recovery from
treatment effects was possible. After 24 and 72 h, embryos were once again
categorized into their specific developmental stages and micrographs were taken.
Progression on to the blastocyst stage was considered to represent full recovery
from treatment.
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Statistical Analysis
All statistical analyses were done with GraphPad Prism version 4.0c software.
Each experiment was repeated a minimum of three times using embryos
collected from replicate groups of mice. Data were presented as the mean ±
standard deviation (SD) for each treatment and each experiment. Two-way RM
ANOVA evaluated data sets with multiple comparisons. P < 0.05 was considered
to be statistically significant.

2.2

Objective Two

To investigate the combinatorial effect of ginsenosides Rb1, Rg1 and Re on
mouse preimplantation development in vitro.

Chemicals
KSOMaa (potassium simplex optimized medium with amino acids) was used for
embryo culture medium (Chemicon, Temecula, CA, USA). Ginsenosides Rb1,
Rg1 and Re were purchased from Sigma (St Louis Mo. USA).

Animals
Female CD1 mice (six-eight weeks old) were purchased from Charles River
(Canada). The experimental design used in objective one was also employed for
the combinatorial ginsenoside experiments.
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Experimental Groups
The two-cell embryos were washed three consecutive times in KSOMaa.
Ginsenoside concentrations were calculated to equal the actual individual
concentrations of Rb1, Rg1 and Re found in the alcoholic extract. 1 mg of purified
ginsenoside Rb1, Rg1 and Re were individually mixed with 1 mL KSOMaa to
prepare three -1000 µg/ml stock solutions. The stock solutions were then used to
prepare a solution for each individual ginsenoside equal to three times the
concentration found in 1000 µg/ml of the alcoholic extract: Rb1 was 493.5 µg/ml;
Rg1 was 7.98 µg/ml; Re was 269.7 0 µg/ml. 0.5 mL of each solution was
combined to give a combinatorial mixture of Rb1, Rg1 and Re equal to 257.1
µg/ml, which was then diluted to provide the five treatment concentrations of
257.1, 64.3, 12.9, 2.6 and 0 µg/ml. In all groups, 20 embryos were cultured in 20
µl drops under oil. All treatment groups were then put into culture at 37°C under a
5% O2, 5% CO2 and 90% N2 atmosphere for 48 h.

The morphological assessment, embryonic recovery and statistical analyses
used in objective one were repeated for the combinatorial ginsenoside
experiments.

2.3

Objective Three

To investigate the safety of consuming both ginseng extracts on pregnancy and
post-partum development in the mouse.
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Chemicals
The AQ and ALC ginseng extracts used were provided by Dr. Edmund Lui’s lab
and prepared according to Azike et al. 2011.

Animals
Female MFI mice (six-eight weeks old) were purchased from Harlan Sciences
(Indiana, USA). Females receiving sham, AQ or ALC treatments were gavaged
(using standard operating procedures as outlined by Western University’s ACVS)
once per day at 9:00 am for 14 days prior to mating, throughout mating and
during gestation. After 14 days of treatment, females were mated with CD1
males. Pregnancy was confirmed by the presence of a vaginal plug where
females were then separated from males and placed into individual cages. If
pregnancy was not confirmed within five days, females were asphyxiated with
CO2, followed by cervical dislocation as outlined above.

Gavaging
Using ACVS standard operating procedures, mice were gavaged with a straight
stainless steel animal feeding needle (24G x 1 inch) attached to a 1 mL syringe.
The mouse was lifted and restrained by grasping the loose skin along the nape of
the neck and back with the thumb and forefinger. In order to determine how far to
insert the needle, the distance from the oral cavity and the end of the xyphoid
process was estimated with the feeding needle on the outside of the animal. The
needle was then inserted into the right lateral side of the oral cavity and gently
inserted into the back of the oral cavity. Gravity alone was used to move the
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needle down the esophagus; the mouse then swallowed the needle. The fluid
was then injected slowly, and the needle was gently removed. The solution
volume administered was calculated in order to assure that no more than 2
mL/100 g body weight was gavaged.

Experimental Groups
In order to prepare the ginseng solutions, 1 mL of distilled water was mixed with
10 mg of the AQ ginseng extract. The same process was followed for the ALC
ginseng extract. When administering a dose of 50 mg/kg, the gavaged volume
was calculated according to individual mouse weights: [0.05 x (weight of mouse) /
10]. When administering a dose of 500 mg/kg, the solutions were prepared 10
times more concentrated (100 mg of each extract was used with 1mL distilled
water). Each experiment consisted of four treatment groups: control-not gavaged,
sham-gavaged water, gavaged aqueous extract and gavaged alcoholic extract.
Two principal experiments were conducted, females gavaged 50mg/kg for 14
days prior to mating and throughout gestation, and females gavaged 500 mg/kg
for 14 days prior to mating and throughout gestation. N values were 3-6 pregnant
mice per treatment group per experiment.

Morphological Assessment
Once litters were born, day of birth, litter size, and gestation period were
determined for each group in each experiment. Pups were also individually
weighed every four days until weaning on post-partum day 20. When pups were
weaned, the sex of the mice was determined.
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Statistical Analysis
All statistical analyses were done with GraphPad Prism version 4.0c software.
Data were presented as the mean ± standard deviation (SD). For litter size,
gestation period and pup sex, statistical analyses were conducted with an
unpaired t test and the n value was 3-6. For pup weight, two-way RM ANOVA
evaluated data sets with multiple comparisons and n values ranged between 201247. P < 0.05 was considered to be statistically significant.
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Results

3.1

Concentration Response Effects of North American Ginseng Extracts and
their Individual Active Compounds on Mouse Preimplantation
Development in Vitro.

3.1.1 The Effect of Aqueous and Alcoholic Ginseng Extract Treatment on
Preimplantation Development.
The effect of North American AQ and ALC ginseng extracts on
preimplantation development in vitro was evaluated by collecting two-cell
embryos from superovulated and inseminated MF1 females, and placing
embryos into culture for 48 hours in 0 (control), 10, 50, 250 and 1000 µg/ml of
both extracts. AQ ginseng extract treatment resulted in a concentration
responsive inhibition of development (Figure 3.1A). As the concentration of
ginseng increased, the numbers of embryos developing to the morula and
blastocyst stages were significantly reduced (p<0.05) with development
increasingly blocking at the two-cell and four-cell stages (figure 3.1A and 3.2A, C,
E, G, I). With the highest concentration of 1000 µg/ml, only 1.5% of embryos
developed to the morula stage, whereas 71.7% and 24.1% of control embryos
progressed to the morula and blastocyst stage consecutively after 48 hours of
culture. Treatment with the ALC extract presented a similar outcome with lower
concentrations of 10, 50 and 250 µg/ml, significantly (p<0.05) increasing the
numbers of embryos blocked in development at the two-cell stage. Interestingly,
treatment with 1000 µg/ml resulted in no significant impairment of embryo
development when compared to the control (figure 3.1B and 3. A, D, F, H, J).
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Figure 3.1

Development of two-cell Mouse Embryos after 48 h Treatment

with Aqueous and Alcoholic Ginseng Extracts. Two-cell embryos were
flushed from the oviduct and placed into culture with the AQ (A) and ALC (B)
ginseng extract for 48 hours. Treatment groups for both extracts consisted of a
KSOMaa control (0 µg/ml), 10, 50, 250 and 1000 µg/ml and were put into culture
at 37°C under a 5% O2, 5% CO2 and 90% N2. Embryonic development was
evaluated after 48 hours and embryos were categorized as being 2-cell, 4-cell, 8cell, 8-cell compacted, morula or blastocysts. Variations in embryo development
between treatment groups are presented as the mean ± SD, representative of
three independent replicates. Significant differences are represented by different
superscripts (P≤0.05).
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Figure 3.2

Morphology of Embryos Following Treatment with Five

different Concentrations of Aqueous and Alcoholic Ginseng Extract for 48
h. Comparative morphology of representative groups of two-cell embryos after
treatment with 0 µg/ml (A, B), 10 µg/ml (C, D), 50 µg/ml (E, F), 250 µg/ml (G, H)
and 1000 µg/ml (I, J) of AQ ginseng extract (A, C, E, G, I) and ALC ginseng
extract (B, D, F, H, J) for 48 hours. Scale bars represent 100 µm.
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Following treatment with AQ and ALC ginseng extracts for 48 hours,
embryos were washed three consecutive times in fresh KSOMaa and returned to
culture in clean drops of culture medium for an additional 72 hours to determine
whether ginseng treatment effects were permanent or reversible. Measuring
progression to the blastocyst stage between control and treatment groups
assessed recovery from treatment. Embryos treated with 10 µg/ml of the AQ
extract displayed the strongest recovery from treatment as blastocyst formation
jumped from 24.1% at 0 h recovery time to 93.8% blastocysts after 72 h of
recovery time. All other AQ treatment groups displayed a significant (p<0.05)
decline in embryo development to the blastocyst stage when compared with the
control, indicative of extremely low recovery potential (Figure 3.3A and 3.4A, B,
E, F, I, J, M, N, Q, R). In contrast, embryos treated with 10, 50 and 1000 µg/ml of
the ALC extract were able to fully recover from treatment by displaying no
significant difference in blastocyst formation between the control and ALC treated
embryos after a 72 hour recovery period. Interestingly, the developmental
blockade resulting from treatment with 250 µg/ml ALC extract was only marginally
reversed with 29.4% of treated embryos developing to the blastocyst stage, as
opposed to 97.1% for control after 72 h of recovery time (Figure 3.3B and 3.4C,
D, G, H, K, L, O, P, S, T). The difference in blastocyst formation between these
two groups was significantly different (p<0.05). All data shown in Figures 3.1 and
3.3 are presented as the mean ± SD, representative of three independent
replicates.
Thus both ginseng extracts negatively affect development to the blastocyst
stage in vitro. The effects of AQ and ALC treatments on development were only
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reversible following low concentration treatments ie 10 ug/ml for AQ extract and
10 and 50 ug/ml for ALC. Interestingly, treatment with 1000 ug/ml ALC did not
negatively affect development to the blastocyst stage.
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Figure 3.3

Percentage of Mouse Embryos that Recovered from Ginseng

Treatment. Embryos treated for 48 h with AQ (A) and ALC (B) ginseng extracts
were washed three consecutive times in KSOMaa and returned to culture in
clean drops of culture media for 72 h. Progression to the blastocyst stage was
considered to represent full recovery from treatment. Differences in embryo
development to the blastocyst stage between treatment groups are presented as
the mean ± SD, representative of three independent replicates. Significant
differences are represented by different superscripts (P≤0.05).
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Figure 3.4

Morphology of Mouse Embryos Following Recovery from

Treatment with Aqueous and Alcoholic Ginseng Extracts. Comparative
morphology of representative groups of embryos following wash out and recovery
from ginseng treatment with 0 µg/ml (A, B, C, D), 10 µg/ml (E, F, G, H), 50 µg/ml
(I, J, K , L), 250 µg/ml (M, N, O, P) and 1000 µg/ml (Q, R, S, T) of aqueous
ginseng extract (A, B, E, F, I, J, M, N, Q, R) and alcoholic ginseng extract (C, D,
G, H, K, L, O, P, S, T) for 24 (A, E, I, M, Q; C, G, K, O, S) and 72 hours (B, F, J,
N, R; D, H, L, P, T). Scale bars represent 100 µm.

49
Aqueous Extract Aqueous Extract Alcoholic Extract
72 h in culture
24 h in culture
24 h in culture

Alcoholic Extract
72 h in culture

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

0
μg/mL

10
μg/mL

50
μg/mL

250
μg/mL

1000
μg/mL

Blastocyst Development

50
3.1.2 The Effect of Treatment with 2000 µg/ml of Aqueous Ginseng Extract
on Preimplantation Development
Since the AQ ginseng extract has half the ginsenoside concentration as
the ALC extract, specifically 138.7 mg/g versus 282.5 mg/g, I next investigated
whether doubling the concentration of the 1000 µg/ml of AQ extract to 2000 ug/ml
would replicate the outcomes observed with 1000 µg/ml of ALC ginseng extract.
two-cell embryos from MF1 females were cultured for 48 hours in 0 (control) and
2000 µg/ml of AQ extract. In contrast to my observations with using 1000 ug/ml
ALC treatment (above), none of the embryos treated with 2000 µg/ml developed
to the morula or blastocyst stages, and all were halted at the two-cell and fourcell stages (Figure 3.5A). Furthermore, significant (p <0.05) differences in
blastocyst formation were observed between control and treated embryos once
the AQ extract treatment was washed out and the cleaned embryos returned to
culture for 72 h (Figure 3.5B). All data in Figure 3.5 are presented as the mean ±
SD, representative of three independent replicates. Thus these outcomes
suggest that the differences in treatment effects between high concentrations of
AQ and ALC on development to the blastocyst stage are unlikely to be due to
differences in ginsenoside concentrations between the two extracts.
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Figure 3.5 Development and Recovery of Two-cell Mouse Embryos Treated
with 2000 µg/ml of Aqueous Ginseng Extract. Two-cell embryos were flushed
from the oviduct and placed into culture with aqueous ginseng extract. Treatment
groups consisted of a KSOMaa control (0 µg/ml) and 2000 µg/ml of the AQ
extract, and were cultured at 37°C under a 5% O2, 5% CO2 and 90% N2
atmosphere for 48 h (A). Embryos were then washed three consecutive times in
KSOMaa and returned to culture in clean drops of culture media for 72 h (B).
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted,
morula or blastocyst after all time points. Progression on to the blastocyst stage
was considered to represent full recovery from treatment. Differences in embryo
development to differing embryonic stages or blastocyst formation between
treatment groups are presented as the mean ± SD, representative of three
independent replicates. Significant differences are represented by different
superscripts (P≤0.05).
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3.1.3 The Effect of Individual Ginsenoside Rb1 Treatment on
Preimplantation Development.
My next experiments focused on attempting to define the primary
constituents of the ginseng extracts that were impeding preimplantation
development in vitro. I began this process by investigating the concentration
response effects of increasing individual ginsenosides Rb1, Rg1 and Re
concentrations on preimplantation development in vitro and concluded these
experiments by investigating the effects of the polysaccharide fraction on early
development.
First, the effect of ginsenoside Rb1 on preimplantation development in
vitro was evaluated. Two-cell embryos from MF1 females were cultured for 48 h
with concentrations of ginsenoside Rb1 equal to those found in the aqueous
extract (Figure 3.6A, B) and alcoholic extract (figure 3.6C, D). AQ level treatment
groups consisted of 0, 0.7, 3.3, 16.6 and 66.2 µg/ml of Rb1. In contrast to the
treatment outcomes with the AQ extracts, treatment with Rb1 alone did not
significantly block embryo development at the two-cell or four-cell stages.
However, there was a significant difference (p<0.05) between the control and
treatment with 16.6 µg/ml Rb1, with the treated group displaying a higher
percentage of morula. This was accompanied by the observation that no embryos
in the treated groups developed to the blastocyst stage after 48 h treatment,
while the control group displayed a 10% blastocyst formation frequency (Figure
3.6A and 3.7A-E). Experimentation using ALC Rb1 treatment levels (0, 1.6, 8.2,
41.1 and 164.5 µg/ml) resulted in a significant variation between the control and
treatment with 8.2 µg/ml of ginsenoside Rb1 (Figure 3.6C). 84.1% of embryos in
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the control group compared to only 65.6% of embryos treated with 8.2 µg/ml
progressed to the morula stage. No other significant differences in embryo
development were observed between the treatment groups (Figure 3.6C and
3.7F-J).
Embryos treated for 48 h with ginsenoside Rb1 were washed out in
KSOMaa and returned to culture in clean drops of culture media for 72 h.
Progression to the blastocyst stage was considered to represent full recovery
from treatment. For both Rb1 experiments (Figure 3.6B and 3.8A-J; Figure 3.6D
and 3.8K-T), while blastocyst formation was low at the 0 h mark, embryos in all
treatment groups were able to recover from treatment and no significant
differences in development were observed between any treatment groups after
72 h in culture. All data shown in figure 3.6 is presented as the mean ± SD,
representative of three independent replicates.
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Figure 3.6

Development and Recovery of Mouse Embryos Following

Treatment with Ginsenoside Rb1. Two-cell embryos were flushed from the
oviduct and placed into culture for 48 h with concentrations of ginsenoside Rb
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment
groups consisted of: 0, 0.7, 3.3, 16.6 and 66.2 µg/ml (A, B); 0, 1.6, 8.2, 41.1 and
164.5 µg/ml (C, D). Embryos were then washed three consecutive times in
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D).
Differences in embryo development to differing embryonic stages or blastocyst
formation between treatment groups are presented as the mean ± SD,
representative of three independent replicates. Significant differences are
represented by different superscripts (P≤0.05).
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Figure 3.7

Morphology of Mouse Embryos Following Rb1 Treatment.

Comparative morphology of representative groups of embryos after 48 h
treatment with concentrations of Rb1 equal to those found in the aqueous (A-E)
and alcoholic (F-J) ginseng extracts. Treatment groups consisted of: 0 (A), 0.7
(B), 3.3 (C), 16.6 (D) and 66.2 µg/ml (E); 0 (F), 1.6 (G), 8.2 (H), 41.1 (I) and
164.5 µg/ml (J). Scale bars represent 100 µm.
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Figure 3.8

Morphology of Mouse Embryos Following Recovery from Rb1

Treatment. Comparative morphology of representative groups of embryos
following wash out and recovery from treatment with 0 µg/ml (A, B and K, L), 0.7
µg/ml (C, D), 3.3 µg/ml (E, F), 16.6 µg/ml (G, H), 66.2 µg/ml (I, J), 1.6 µg/ml (M,
N), 8.2 µg/ml (O, P), 41.1 µg/ml (Q, R) and 164.5 µg/ml (S, T) of ginsenoside Rb1
for 24 (A-J) and 72 hours (K-T). Scale bars represent 100 µm.
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3.1.4 The Effect of Individual Ginsenoside Rg1 Treatment on
Preimplantation Development.
Two-cell embryos from MF1 females were cultured for 48 h with
concentrations of ginsenoside Rg1 equal to those found in the aqueous extract
(Figure 3.9A, B) and alcoholic extract (Figure 3.9C, D). AQ levels consisted of 0,
0.13, 0.66, 2.66 and 13.1 µg/ml. Treatment with Rg1 at AQ levels for 48 h
resulted in no significant differences (p< 0.05) in embryonic development
between any of the treatment groups (Figure 3.9A and 3.10A-E). ALC Rg1
treatment group levels included 0, 0.03, 0.15, 0.66 and 2.66 µg/ml. The most
notable difference in developmental outcomes occurred between the control
group, where 90.5% of embryos progressed to the morula stage whereas in the
lowest concentration treatment of 0.03 µg/ml, only 71% of the embryos treated
with Rg1 progressed to the morula stage. In addition, development to the morula
stage varied significantly (p<0.05) between treatment with concentrations of 0.03,
0.66 and 2.66 µg/ml as well as 0.66 and 2.66 µg/ml of ginsenoside Rg1 (Figure
3.9C and 3.10F-J).
Embryos treated for 48 h with ginsenoside Rg1 were then washed three
consecutive times in KSOMaa and returned to culture in clean drops of culture
media for 72 h. No significant differences in blastocyst development were
observed between controls, and any of the AQ Rg1 treatment groups (Figure
3.9B and Figure 3.11A-J). In contrast, within the ALC Rg1 treatment groups,
blastocyst formation was delayed for the 0.03 and 0.15 µg/ml Rg1 treatments in
comparison to the control at the 24 h time point. However, after 72 h in culture,
no significant differences in blastocyst development between groups were
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observed (figure 3.9D and 3.11K-T). All data shown in Figure 3.9 is presented as
the mean ± SD, representative of three independent replicates.
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Figure 3.9

Development and Recovery of Mouse Embryos Following

Treatment with Ginsenoside Rg1. Two-cell embryos were flushed from the
oviduct and placed into culture for 48 h with concentrations of ginsenoside Rg1
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment
groups consisted of: 0, 0.13, 0.66, 2.66 and 13.1 µg/ml (A, B); 0, 0.03, 0.15, 0.66
and 2.6 µg/ml (C, D). Embryos were then washed three consecutive times in
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D).
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted,
morula or blastocyst after all time points. Progression on to the blastocyst stage
was considered to represent full recovery from treatment. Differences in embryo
development to differing embryonic stages or blastocyst formation between
treatment groups are presented as the mean ± SD, representative of three
independent replicates. Significant differences are represented by different
superscripts (P≤0.05).
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Figure 3.10 Morphology of Mouse Embryos Following Rg1 Treatment.
Comparative morphology of representative groups of embryos after 48 h
treatment with concentrations of Rg1 equal to those found in the aqueous (A-E)
and alcoholic (F-J) ginseng extracts. Treatment groups consisted of: 0 (A), 0.13
(B), 0.66 (C), 2.66 (D) and 13.1 µg/ml (E); 0 (F), 0.03 (G), 0.15 (H), 0.66 (I) and
2.6 µg/ml (J). Scale bars represent 100 µm.
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Figure 3.11 Morphology of Mouse Embryos Following Recovery from Rg1
Treatment. Comparative morphology of representative groups of embryos once
recovered from treatment with 0 µg/ml (A, B and K, L), 0.13 µg/ml (C, D), 0.66
µg/ml (E, F), 2.66 µg/ml (G, H), 13.1 µg/ml (I, J), 0.03 µg/ml (M, N), 0.15 µg/ml
(O, P), 0.66 µg/ml (Q, R) and 2.6 µg/ml (S, T) of ginsenoside Rg1 for 24 (A-J)
and 72 hours (K-T). Scale bars represent 100 µm.
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3.1.5 The Effect of Individual Ginsenoside Re Treatment on
Preimplantation Development.
Two-cell embryos from MF1 females were cultured for 48 h with
concentrations of ginsenoside Re equal to those found in the aqueous extract
(Figure 3.12A, B) and the alcoholic extract (Figure 3.12C, D). Treatment groups
consisted of: 0, 0.6, 2.8, 14.0 and 55.9 µg/ml for AQ Re levels and 0, 0.9, 4.5,
22.4 and 89.9 µg/ml for ALC Re levels. For all treatments, including 72 h
recovery, with both AQ Re and ALC Re concentrations, no significant variations
in embryo development between the control and treatment groups were observed
(Figure 3.12A,C and 3.13; Figure 3.12B and 3.14A-J; Figure 3.12D and 3.14K-T).
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Figure 3.12 Development and Recovery of Mouse Embryos Following
Treatment with Ginsenoside Re. Two-cell embryos were flushed from the
oviduct and placed into culture for 48 h with concentrations of ginsenoside Re
equal to those found in the aqueous (A) and alcoholic (C) extracts. Treatment
groups consisted of: 0, 0.6, 2.8, 14 and 55.9 µg/ml (A, B); 0, 0.9, 4.5, 22.4 and
89.9 µg/ml (C, D). Embryos were then washed three consecutive times in
KSOMaa and returned to culture in clean drops of culture media for 72 h (B, D).
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted,
morula or blastocyst after all time points. Progression on to the blastocyst stage
was considered to represent full recovery from treatment. No significant
differences were observed between treatment groups.
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Figure 3.13 Morphology of Mouse Embryos Following Re Treatment.
Comparative morphology of representative groups of embryos after 48 h
treatment with concentrations of Re equal to those found in the aqueous (A-E)
and alcoholic (F-J) ginseng extracts. Treatment groups consisted of: 0 (A), 0.6
(B), 2.8 (C), 14.0 (D) and 55.9 µg/ml (E); 0 (F), 0.9 (G), 4.5 (H), 22.4 (I) and 89.6
µg/ml (J). Scale bars represent 100 µm.
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Figure 3.14 Morphology of Mouse Embryos Following Recovery from Re
Treatment. Comparative morphology of representative groups of embryos
following recovery period with 0 µg/ml (A, B and K, L), 0.6 µg/ml (C, D), 2.8
µg/ml (E, F), 14.0 µg/ml (G, H), 55.9 µg/ml (I, J), 0.9 µg/ml (M, N), 4.5 µg/ml (O,
P), 22.4 µg/ml (Q, R) and 89.6 µg/ml (S, T) of ginsenoside Re for 24 (A-J) and 72
hours (K-T). Scale bars represent 100 µm.
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3.1.6 The Effect of Treatment with the Polysaccharide Fraction (PSF) on
Preimplantation Development.
Two-cell embryos from CD1 females were cultured for 48 hours in 0
(control), 1.5, 7.5, 37.5 and 150 µg/ml of PSF. No significant differences in
embryo development were identified when comparing preimplantation
developmental progression between treatment groups (Figure 3.15A and 3.16A,
D, G, J, M). Notably, after 48 h in treatment, a much higher percentage of
embryos developed to the blastocyst stage for all groups than observed in all
other previous experiments. This is likely due to the fact that embryos cultured
with PSF were from CD1 and not MFI females that were used for all previous
experiments. CDI and MFIs are both outbred lines of mice that are commonly
used to generate preimplantation embryos for research purposes. We have
preferred MF1s simply because they display a more robust response to hormonal
superovulation and thus allow for the collection of greater numbers of oocytes
and embryos from fewer mice than CD1s do. No differences in development have
been reported in the literature to date for embryos derived from these lines,
however we have noted that CDI embryos do develop faster in vitro than MF1
embryos. Our supplier of MF1 mice (Harlan Inc) has discontinued offering them
due to the small number of labs around the world that use these mice. Thus we
have had to shift exclusively to CD1 mice for all further experiments conducted in
the lab.
Embryos treated for 48 h with PSF were not affected by the treatment and
developed normally. Once washed 3 consecutive times in KSOMaa and returned
to culture in clean drops of culture media for 72 h, natural development continued
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and no significant variations in blastocyst formation were noted between any
treatment groups (Figure 3.15B and 3.16B, C, E, F, H, I, K, L, N, O). All data
shown in Figure 3.15 is presented as the mean ± SD, representative of three
independent replicates. Thus the overall conclusion from all of the single agent
treatment experiments is that no single agent replicates the collective effects of
AQ or ALC extract treatment observed on preimplantation development. Thus the
negative impact on development observed from AQ and ALC treatment must
stem from the collective effects of several of the ginseng extract components
acting on the early embryo and restricting development.

78
Figure 3.15 Development and Recovery of Mouse Embryos Treated with
PSF. Two-cell embryos were flushed from the oviduct and placed into culture with
PSF. Treatment groups consisted of KSOMaa control (0 µg/ml), 1.5, 7.5, 37.5
and 150 µg/ml and were cultured at 37°C under a 5% O2, 5% CO2 and 90% N2
atmosphere for 48 h (A). Embryos were then washed three consecutive times in
KSOMaa and returned to culture in clean drops of culture media for 72 h (B).
Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted,
morula or blastocyst after all time points. Progression on to the blastocyst stage
was considered to represent full recovery from treatment. No significant
differences were observed between treatment groups.

79

A

B

48 h Treatment with Polysaccharide Fraction

72 h Recovery with Polysaccharide Fraction

80
Figure 3.16 Morphology of Embryos Following PSF Treatment. Comparative
morphology of representative groups of mouse Two-cells after treatment for 48 h
(A, D, G, J, M) and recovery for 24 h (B, E, H, K, N) and 72 h (C, F, I, L, O) with
0 µg/ml (A, B, C), 1.5 µg/ml (D, E, F), 7.5 µg/ml (G, H, I), 37.5 µg/ml (J, K, L) and
150 µg/ml (M, N, O) of PSF. Scale bars represent 100 µm.
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3.2

Investigate the Combinatorial Effect of Ginsenosides Rb1, Rg1 and Re on
Mouse Preimplantation Development in Vitro
Two-cell embryos from CD1 females were cultured for 48 hours in 0

(control), 2.6, 12.9, 64.3 and 257.1 µg/ml of a combinatorial solution of Rb1, Rg1
and Re. No significant differences in embryo development were identified when
comparing preimplantation developmental progression between treatment groups
(Figure 3.17A and 3.18A, D, G, J, M). Notably, after 48 h in treatment, a much
higher percentage of embryos developed to the blastocyst stage for all groups
than observed in most other previous experiments. This is likely due to the fact
that embryos cultured with the combinatorial solution were from CD1 and not MFI
females that were used for the experiments outlined above. CDI embryos simply
develop faster in vitro than MF1 embryos, which accounts for the higher
blastocyst formation rate.
Embryos treated for 48 h with a combination of Rb1, Rg1 and Re were not
affected by the treatment, and developed normally. Embryos were then washed
three consecutive times in KSOMaa and returned to culture in clean drops of
culture media for 72 h. While blastocyst formation for embryos treated with 64.3
µg/ml was reduced compared to embryos treated with 12.9 µg/ml, no significant
variations in blastocyst development were observed between the control and any
treatment groups at any time points throughout recovery (Figure 3.17B and
3.18B, C, E, F, H, I, K, L, N, O). All data shown in Figure 3.17 is presented as the
mean ± SD, representative of three independent replicates. Thus the overall
conclusion from the experiment with the combinatorial ginseng solution is that the
collective effects of AQ and ALC extract treatment observed on preimplantation
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development are not due to this particular combination of ginsenosides.
Therefore, the negative impact on development observed from AQ and ALC
treatment must stem from a ginsenoside or non-ginsenoside compound that has
not been investigated in this project, or the collective effects of several of the
ginseng extract components acting on the early embryo and restricting
development.
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Figure 3.17 Development and Recovery of Mouse Embryos Treated with a
Combinatorial Solution of Ginsenosides Rb1, Rg1 and Re. Two-cell embryos
were flushed from the oviduct and placed into culture with a combination of Rb1,
Rg1 and Re. Treatment groups consisted of KSOMaa control (0 µg/ml), 2.6, 12.9,
64.3 and 257.1 µg/ml and were cultured at 37°C under a 5% O2, 5% CO2 and
90% N2 atmosphere for 48 h (A). Embryos were then washed three consecutive
times in KSOMaa and returned to culture in clean drops of culture media for 72 h
(B). Embryos were categorized as being 2-cell, 4-cell, 8-cell, 8-cell compacted,
morula or blastocyst after all time points. Progression on to the blastocyst stage
was considered to represent full recovery from treatment. No significant
differences were observed between treatment groups.
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Figure 3.18 Morphology of Embryos Following Treatment with a
Combinatorial Solution of Ginsenosides Rb1, Rg1 and Re. Comparative
morphology of representative groups of mouse two-cells after treatment for 48 h
(A, D, G, J, M) and recovery for 24 h (B, E, H, K, N) and 72 h (C, F, I, L, O) with
0 µg/ml (A, B, C), 2.6 µg/ml (D, E, F), 12.9 µg/ml (G, H, I), 64.3 µg/ml (J, K, L)
and 257.1 µg/ml (M, N, O) of a combinatorial solution of Rb1, Rg1 and Re. Scale
bars represent 100 µm.
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3.3

Determine the Safety of consuming both Ginseng Extracts on Pregnancy
and Post-Partum Development in the Mouse
The effects of treatment with AQ or ALC extract on mouse preimplantation

development in vitro vary substantially from the reports of effects of treatment on
mouse pregnancy and post-partum development using Red Korean ginseng.
Thus it was essential to extend my studies and conduct in vivo experiments using
North American ginseng to determine the effects, if any, of these extracts on
pregnancy and post-partum development in the mouse.

3.3.1 Females Gavaged with 50 mg/kg of Ginseng Extracts for Two Weeks
prior to Mating and throughout Gestation.
Female MF1 mice were placed into control (no gavage), sham (water
gavage) and experimental treatments (gavage of 50 mg/kg of either AQ or ALC
ginseng extract) each day for two weeks prior to mating and throughout
gestation. 3-6 experimental replicates were carried out for each treatment group.
Gestational day 0 was established by the presence of a vaginal plug after mating.
Following parturition, the gestation period (average of 19 days for control) (Figure
3.19A) and litter size (average of 12.75 pups per litter for control) (Figure 3.19B)
were determined. Developmental growth was then assessed and pups were
weaned and sexed on post-partum day 20. The percentage of males and females
in each litter was compared between different treatment groups, and the sex ratio
was determined (Figure 3.19C). No significant differences were observed
between treatment groups for gestation period, litter size or sex ratio.
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Pup growth rate was determined by weighing 247 individual pups every
four days from birth to post-partum day 20. Differences in pup weight among the
treatment groups were observed beginning on post partum day four. While none
of these variations in growth were significantly different among the treatment
groups, they persisted until day 20 post partum (Figure 3.20A). To determine
whether the differences in development observed in Figure 3.20A are due to
possible variations in growth rates amid males and females, weight was recorded
according to sex on day 20. There were no significant differences in male pup
weight on post-partum day 20 between any treatment groups (Figure 3.20B).
However, pup weight did vary significantly between the control (average of 14.1g)
and ALC (average of 13.3g) groups of female pups on post-partum day 20
(Figure 3.20C). All data shown in Figure 3.19 and 3.20 are presented as the
mean ± SD.
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Figure 3.19 The Effect of Pre-Pregnancy and Gestational Ginseng
Treatment (50 mg/kg) on Pregnancy and Post-Partum Development. Female
MF1 mice were placed into control (no gavage), sham (water gavage) and
experimental treatments (gavage of 50 mg/kg of either AQ or ALC ginseng
extract) for two weeks prior to mating and throughout gestation. Following
parturition, gestation period in days (A) and number of pups per litter (B) were
determined for each female. Pups were then sexed on post-partum day 20 and
the percentage of males vs. females in each litter was evaluated (C). Differences
in gestation period, litter size and sex ratio between treatment groups are
presented as the mean ± SD, representative of 3-6 independent replicates. No
significant differences were observed between treatment groups.

91

A

Gestation for Mice Gavaged with 50 mg/kg Ginseng

B

Litter Size for Mice Gavaged with 50 mg/kg Ginseng

C

Sex Ratio between Treatment Groups

92
Figure 3.20 The Effect of Pre-Pregnancy and Gestational Ginseng
Treatment (50 mg/kg) on Post-Partum Pup Weight and Growth. Female MF1
mice were placed into control (no gavage), sham (water gavage) and
experimental treatments (gavage of 50 mg/kg of either AQ or ALC ginseng
extract) for 20 weeks prior to mating and throughout gestation. Following
parturition, pups were individually weighed every four days until weaning on postpartum day 20 (A). Once weaned, pups were sexed and weight was recorded
according to sex in order to determine differences between male (B) and female
(C) developmental weight gain between treatment groups. Differences in pup
growth between treatment groups are presented as the mean ± SD,
representative of 49-77 (A) and 3-6 (B, C) independent replicates. Significant
differences are represented by different superscripts (P≤0.05).
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3.3.2 Females Gavaged with 500 mg/kg of Ginseng Extracts for Two Weeks
prior to Mating and throughout Gestation.
Female MF1 mice were placed into control (no gavage), sham (water
gavage) and experimental treatments (gavage of 500 mg/kg of either AQ or ALC
ginseng extract) each day for two weeks prior to mating and throughout
gestation. 3-6 experimental replicates were carried out for each treatment group.
Gestational day 0 was established by the presence of a vaginal plug after mating.
Following parturition, significant (p<0.05) variations in gestation period were
noted between the control and both AQ and ALC groups, with a difference of 0.78
and 1 day respectively. Furthermore, a significant difference (p<0.05) of 0.68
days was observed between the sham and ALC groups (Figure 3.21A). The
average number of pups per litter between treatment groups also varied
significantly (p<0.05) between the control (15.03 pups per litter) and sham (12
pups per litter) treatments, supporting our observation that gavage can influence
gestation period (Figure 3.21B). No significant differences in sex ratio were
detected in any of the treatment groups on day 20 post-partum (Figure 3.21C).
To evaluate pup growth and development, 212 individual pups were
weighed every four days from birth to post-partum day 20. No significant
differences (p<0.05) were observed in pup weight among treatment groups until
post-partum day 20. On day 20 post-partum there was a significant (p<0.05)
difference between the ALC treatment and the three other groups (control, sham
and AQ) (Figure 3.22A). To determine whether the observed differences in
weight were due to possible variations in growth between males and females,
weight was determined for each sex on day 20. A significant difference (p<0.05)
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in male pup weight was observed on post-partum day 20 between the sham
(mean = 13.4g) and ALC (mean = 15g) groups (Figure 3.22B). However, no
significant differences in female pup weight on post-partum day 20 were
observed between any treatment groups (Figure 3.22C). All data shown in Figure
3.21 and 3.22 are presented as the mean ± SD. Overall the results support a
cautionary approach to determining whether ginseng extract consumption has a
negative influence on pregnancy and post-partum development. Gavaging
certainly has major influence on gestation term and litter size, however
independent effects of AQ and ALC extracts on gestation period and pup growth
were also observed. In addition, the effects of ginseng consumption display some
signs of gender bias, especially on weight gain.
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Figure 3.21 The Effect of Pre-Pregnancy and Gestational Ginseng
Treatment (500 mg/kg) on Pregnancy and Post-Partum Development.
Female MF1 mice were placed into control (no gavage), sham (water gavage)
and experimental treatments (gavage of 500 mg/kg of either AQ or ALC ginseng
extract) for two weeks prior to mating and throughout gestation. Following
parturition, gestation period in days (A) and number of pups per litter (B) were
determined for each female. Pups were then sexed on post-partum day 20 and
the percentage of males vs. females in each litter was evaluated (C). Differences
in gestation period, litter size and sex ratio between treatment groups are
presented as the mean ± SD, representative of 3-6 independent replicates.
Significant differences are represented by different superscripts (P≤0.05).
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Figure 3.22 The Effect of Pre-Pregnancy and Gestational Ginseng
Treatment (500 mg/kg) on Post-Partum Pup Weight and Growth. Female
MF1 mice were placed into control (no gavage), sham (water gavage) and
experimental treatments (gavage of 500 mg/kg of either AQ or ALC ginseng
extract) for two weeks prior to mating and throughout gestation. Following
parturition, pups were individually weighed every four days until weaning on postpartum day 20 (A). Once weaned, pups were sexed and weight was recorded
according to sex in order to determine differences between male (B) and female
(C) developmental weight gain between treatment groups. Differences in pup
growth between treatment groups are presented as the mean ± SD,
representative of 27-66 (A) and 3-6 (B, C) independent replicates. Significant
differences are represented by different superscripts (P≤0.05).
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Discussion

4.1

Concentration Response Effect of the Aqueous and Alcoholic Ginseng

Extracts derived from North American Ginseng on Mouse Preimplantation
Development in Vitro.
Ginseng is a natural herbal product and its consumption and inclusion as
part of a healthy diet is on a dramatic rise worldwide. Due to the many purported
health benefits associated with this herb, it is one of 10 most commonly used
herbal medicines in the United States (Bent and Ko 2004). Women are the
predominant users of herbal medicines (MacLennan et al. 1996; Eisenberg et al.
1998; Ernst and White 2000). In a US survey, 9.1% of pregnant women declared
the use of these products during their current pregnancy (Gibson et al. 2001). In
China, as high as 15% of women consumed ginseng during pregnancy with the
primary reason being that it is believed to be “good for pregnancy and the fetus”
(Ong et al. 2005). Due to the lack of information on the safety of ginseng
consumption during pregnancy, its effects on preimplantation development,
pregnancy and post-partum development were assessed in this present study. In
summation, it was discovered that AQ and ALC ginseng extract treatments
caused a concentration dependent inhibition of development when applied
directly to preimplantation embryos in culture. Experiments were repeated with
individual ginsenosides, and ginsenosides Rb1 and Rg1 reduced the number of
embryos progressing to the morula stage at low concentrations. Importantly,
pregnancy and post-partum development were affected with an orally
administered high dose of 500 mg/kg of North American ginseng (NAG) extracts.
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This study indicates that direct exposure to ginseng extracts is detrimental to the
completion of normal early mammalian development.
The effect of ginseng and ginsenosides on postimplantation embryos has
been examined (Chan et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006; Lee et al.
2008), however its direct influence on preimplantation embryo development and
thus embryo implantation, has not been investigated to date. Furthermore, most
experiments determining ginseng’s effect on reproduction were undertaken with
Korean or Chinese ginseng. North America is known to now produce some of the
most potent forms of ginseng, and this is becoming an important agricultural crop
as well as a sought after herbal medicine. It is thus essential that research
investigate the safety of NAG on reproduction and pregnancy. Furthermore, due
to such differences in composition between the AQ and ALC extracts (as
previously described), it is important to investigate both extracts separately. In
this present study, the effects of AQ and ALC extracts derived from North
American ginseng, as well as the influence of its individual active compounds on
preimplantation development in the mouse were assessed. Treatment with the
AQ ginseng extract resulted in a concentration-dependent inhibition of
development after 48 h in culture. Treatment with the lowest concentration of 10
µg/ml of AQ extract did not affect embryo development, however 50, 250 and
1000 µg/ml AQ extract levels increasingly halted development at the two-cell and
four-cell stages. Furthermore, recovery potential was extremely low for these
three treatments and a significant blockade of blastocyst development was
observed. Treatment with the ALC extract produced similar outcomes. The main
variation between treatments with the two types of extracts was observed with
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the 1000 µg/ml ALC concentration. It is challenging to understand the
mechanistic basis for the observed difference in outcomes using the 1000 ug/ml
concentration of both ginseng extracts, however one main difference between
both extracts is that the ALC extract contains twice the levels of ginsenosides as
the AQ extract. We have very little understanding regarding the precise
mechanism for ginseng extract action on any cell system, including the early
embryo. However, my outcomes from the ALC extract experiment are
reminiscent of several types of ligand/receptor interactions where high levels of
ligand result in receptor desensitization and loss of ligand treatment effects. Of
course this is speculation and requires a great deal more research to fully
understand, but it may be possible that the highest ALC concentration did not
impair development simply because of concentration effects on cell
ligand/receptor signaling systems. The identity of those ligand/receptor
interactions requires extensive new research to uncover them.
In addition each extract has a unique composition. For example, the AQ
extract has less Rb1, Rb2, Rc, Rd and Re, has greater levels of Rg1, and is
composed of 15% PS, whereas the ALC extract does not contain PS. Due to the
complex composition of ginseng products, the precise compound and mechanism
causing the blockade in development is not known, but certainly should become
a focus for further research in this area. Thus the active ingredient halting
embryonic development and causing the different outcomes observed for both
extracts may not necessarily be due to a specific ginsenoside or PS but to other
compounds found in the extract as well as a possible combination of certain
composites. Finally, excluding embryos treated with 250 µg/ml, all other groups
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treated with the ALC extract recovered from the 48 h treatment and progressed
onto the blastocyst stage after 72 h recovery. The fact that embryonic
development was not as severely affected by ALC treatment as that observed
with the AQ extract may have provided these embryos with a better opportunity to
offset any negative treatment effects and continue their normal progression to the
blastocyst stage once removed from treatment.
As previously mentioned, the ALC ginseng extract has double the
concentration of ginsenosides as the AQ extract. Embryos were treated with
2000 µg/ml of the AQ ginseng extract, which has the same total ginsenoside
concentration as 1000 µg/ml of ALC, in order to determine whether the lack of
influence imparted by ALC treatment at this concentration was due to a protective
benefit of high ginsenoside levels. However, the ALC outcomes were not
replicated in this experiment, and instead of observing no negative effect on
development from the AQ extract, treatment effects were amplified and none of
the embryos treated with 2000 µg/ml developed to the morula or blastocyst
stages as all were halted at the two-cell and four-cell stages. Furthermore, none
of the embryos recovered from this treatment. Taken together, these results
suggest that the absence of an effect on embryonic development with 1000 µg/ml
of ALC is not simply due to higher total ginsenoside concentrations, but likely due
to a combination of composites or non-ginsenoside compounds distinct from that
found in the AQ extract. In conclusion, the detrimental effect observed on
embryonic development induced by treatment with the AQ and ALC ginseng
extracts is concentration dependent, and direct embryo exposure to ginseng
extracts is embryotoxic and thus detrimental to preimplantation development.
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Furthermore, once removed from treatment, embryo recovery is limited if possible
at all, and most embryos are not able to resume development once halted at the
two-cell and four-cell stages.

4.2

Concentration Response Effect of the Polysaccharide Fraction and

Individual Ginsenosides Rb1, Rg1, and Re on Mouse Preimplantation
Development in Vitro.
My subsequent experiments focused on attempting to define the primary
constituents of the ginseng extracts that were impeding preimplantation
development in vitro. The exact compound(s) responsible for the embryonic
developmental delay observed with the AQ and ALC ginseng extracts have yet to
be identified due to the complexity of the ginseng plant and all the products
derived from it. Due to the fact that ginsenosides are the major bioactive
component in ginseng and so much research has been centered around their
effects on reproduction (Chan et al. 2003, 2004; Liu et al. 2005a, 2005b, 2006;
Lee et al. 2008), embryos were treated with individual ginsenosides Rb1, Rg1
and Re in order to determine their individual effect on preimplantation
development. Each ginsenoside has a unique chemical structure, which is the
foundation for their different pharmacological and physiological effects in the
body (Sievenpiper et al. 2003). Experiments conducted with Rb1 (PD), Rg1 and
Re (PT) also assured that both major ginsenoside groups, protopanaxadiols and
protopanaxatriols (Tawab et al. 2010) were being tested. In addition, these
ginsenosides are extensively researched due to high concentrations found in
most ginseng species, including AQ and ALC extracts, which made them an ideal
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starting point for assessing the primary constituents of the ginseng extracts that
could be impeding preimplantation development in vitro.
Rb1 is the major ginsenoside found in North American Ginseng (NAG) and
is representative of the PD group (Tawab et al. 2010). Previous studies have
investigated the direct effect of ginsenoside Rb1 on organogenesis in
postimplantation embryos, and have reported that Rb1 treatment significantly
reduces the total morphological scores of rat and mouse embryos when using
concentrations ≥ 30 µg/ml. In addition, the detrimental effect on morphogenesis
was concentration dependent (Chan et al. 2003; Liu et al. 2005). In my study,
preimplantation embryos treated with Rb1 displayed a reduced rate of
development to the morula stage when compared to the control. However this
effect was not concentration dependent and was only observed with a low
concentration of 8.2 µg/ml. Furthermore, all embryos recovered from treatment
and progressed to the blastocyst stage.
Rg1 is found in highest concentrations in the AQ ginseng extract derived
from NAG and is representative of the PT group. Liu et al. 2006 investigated the
effect of Rg1 on postimplantation embryos, and found that it remarkably
decreased the total morphological score of mouse and rat embryos when
concentrations of 30 and 50 µg/ml were tested. Furthermore, postimplantation
embryonic growth was affected using concentrations as low as 10 µg/ml. In my
present study however, the only significant difference in development was
observed between the control and embryos treated with 0.03 µg/ml of Rg1.
Furthermore, while blastocyst formation was delayed for groups treated with 0.03
and 0.15 µg/ml during recovery, all embryos recovered from treatment after 72 h
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in culture. In contrast to Liu et al. 2006, the embryonic developmental delay was
not concentration dependent and was only observed in the 0.03 µg/ml treatment.
Future studies investigating the effects of Rg1 on early development should
consider the use of higher concentration treatments. Thus my study certainly
varied from the outcomes presented in the Liu et al. 2005 and 2006 studies
showing effects of Rb1 and Rg1 treatment on postimplantation development, as I
only observed treatment effects on preimplantation embryos using lower
concentrations of either ginsenoside, and the effects were not concentration
dependent. I obtained the individual Rg1 and Rb1 ginsenosides from Sigma
chemical company, and it is advertised to be a highly purified form of each
ginsenoside. It is possible the purity of the ginsenoside samples varied between
my study and Liu et al 2005 and 2006, which may account for the variation in
outcomes between the studies. Even though I observed some restriction of
development with low concentrations of Rb1 and Rg1, the fact that all embryos
readily recovered from treatment and demonstrated a normal progression to the
blastocyst stage lead me to conclude that treatment with Rb1 or Rg1 alone does
not replicate the outcomes observed following treatment with complete AQ or
ALC extracts on preimplantation development.
Re is the second most prominent ginsenoside found in NAG extracts and
is representative of the PT group. According to Chan et al. 2004, Re exerts a
strong postimplantation embryotoxic effect starting with concentrations of 50
µg/ml. Re treatment severely disrupted development and was associated with a
significant reduction in the morphological scores of rat post implantation embryo
development (Chan et al. 2004). Contrastingly, when evaluating the effect of
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ginsenoside Re on preimplantation development in vitro, no significant delays in
embryonic development between the control and any treatment groups were
found, even for high concentrations up to 89.6 µg/ml.
Finally, the influence of the PSF separated from the AQ ginseng extract on
preimplantation development has not been investigated until now. In my present
study, the effect of five different concentrations of PSF after 48 h in culture was
determined. No significant inhibition of embryonic development was observed,
even for concentrations up to 150 µg/ml. All treated embryos developed naturally
and progressed to blastocyst stage once the extract was washed out and
embryos were placed into fresh medium for 72 h. Thus the overall conclusion
from all of the single agent treatment experiments is that while treatment with
ginsenoside Rb1 and Rg1 using low concentrations certainly halted
preimplantation development, neither these effects or the effect of treatment with
Re or PSF negatively affected development overall. Therefore no single
ginsenoside replicated the collective effects of AQ or ALC extract treatment
observed on preimplantation development. Thus the impact on preimplantation
development observed from AQ and ALC treatment must either result from an
individual non-ginsenoside component not yet identified and experimented with or
the collective effects of several of the ginseng extract components acting on the
early embryo and impeding healthy embryonic development.

4.2

The Combinatorial Effect of Ginsenosides Rb1, Rg1 and Re on Mouse

Preimplantation Development in Vitro
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My subsequent experiments focused on attempting to define whether a
combinatorial solution of ginsenosides could be responsible for the
developmental blockade observed when preimplantation embryos were directly
exposed to AQ and ALC ginseng extracts in vitro. As previously shown, individual
ginsenoside and PSF treatment did not replicate the effects observed when
embryos were treated with whole extracts. Thus a combinatorial solution of Rb1,
Rg1 and Re was used to treat the embryos for 48 h, in order to determine
whether the developmental delay was due to the additive effects of a combination
of ginsenosides. The effect of a combination of Rb1, Rg1 and Re on
preimplantation development and reproduction has not been investigated until
now. In my study, embryos were cultured with five different concentrations of the
combinatorial solution for 48 h. No significant inhibition of embryonic
development was observed for concentrations up to 257.1 µg/ml. Furthermore, all
treated embryos developed naturally and progressed to the blastocyst stage once
the extract was washed out and embryo was placed into fresh medium for 72 h.
Thus the overall conclusion from this experiment is that treatment with a
combination of ginsenosides Rb1, Rg1 and Re did not replicate the collective
effects of AQ or ALC extract treatment observed on preimplantation
development. Thus the impact on preimplantation development observed from
AQ and ALC treatment must either result from a non-ginsenoside component not
yet identified and experimented with or the collective effects of several of the
ginseng extract compounds acting on the early embryo and impeding healthy
embryonic development. Future experiments should be directed at determining
the origin of the effects of ginseng extract treatment on preimplantation
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development, even if oral consumption and in vivo studies do not indicate that
ginseng consumption is detrimental to pregnancy and post-partum development.

4.4

Determine the Safety of Consuming both Ginseng Extracts on Pregnancy

and Post-Partum Development in the Mouse
My results are the first to indicate that direct exposure to ginseng extracts
is detrimental to preimplantation development. These outcomes are in sharp
contrast to findings from in vivo studies investigating the influence of Red Korean
Ginseng treatment two weeks before mating and throughout gestation on
pregnancy in the mouse (Shin et al. 2010). It was determined that embryonic
implantation and fetal growth were not negatively affected (Shin et al. 2010). Due
to these discrepancies in outcomes between my culture study and Shin et al.
2010, it was essential to conduct in vivo experiments using NAG to determine the
effects, if any, of these extracts on pregnancy and post-partum development in
the mouse. Furthermore, since there are usually dose limitations in human
studies, a lower cdose of 50 mg/kg as well as an extremely high dose of 500
mg/kg (≈ 50 times the clinical recommended daily dose by KFDA) were
investigated.
The first experiment consisted of treatment with 50 mg/kg of NAG extracts.
Following parturition, the gestation period and litter size were determined as well
as the sex ratio of mice weaned on post-partum day 20. No significant differences
were observed between any treatments. Lastly, pup growth rate was determined
by weighing individual pups every four days from birth to post-partum day 20 and
no significant differences were observed between groups. In the second
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experiment, females were gavaged with 500 mg/kg of ginseng extracts for two
weeks prior to mating and throughout gestation. Interestingly, a significant
difference of 0.68 days was observed between the sham and ALC group for
gestation period. This difference of 0.68 days in mouse gestation would translate
into nearly 9.5 days difference if a comparable effect were observed in humans.
The average number of pups per litter between treatment groups also varied
significantly between the control and gavaged treatments, implying that the
gavage procedure certainly had some potential for affecting litter size. No
significant differences in sex ratio were detected in any of the treatment groups.
Additionally, pup growth rates from birth to post partum-day 20 were evaluated,
and no developmental variations were observed in pup weight among treatment
groups until post-partum day 20, where a significant difference between the ALC
treatment and the three other groups (control, sham and AQ) was observed. To
determine whether the observed difference in weight was due to possible
variations in growth between males and females, weight was determined for each
sex on day 20. While no differences were observed between treatment groups for
female weight, a significant difference in male pup weight was observed on postpartum day 20 between the sham and ALC groups, indicating that pup growth
rate differences may have been primarily due to variations in male weight, and
not female growth. These results indicate that in vivo ALC ginseng treatment at
very high dose of 500 mg/kg throughout gestation affect gestation period and
also pup post-partum growth.
Thus, clear differences between administration of 50 and 500 mg/kg of
both ginseng extracts were observed. It seems that while treatment with a low
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dose does not affect pregnancy and post-partum development in vivo, a high
dose of 500 mg/kg of the ALC ginseng extract does increase gestation period
and pup growth rates. The importance of these doses is uncertain. Most
recommended levels for ginseng product consumption range from 1-2 g per day,
indicating that a 100 kg person would have to ingest 50 g of ginseng daily to
equal the 500 mg/kg level that I gavaged. Thus, even the 50 mg/kg/day is still
high, however it is much closer to realistic consumption levels. In addition, my in
vivo results contrast dramatically with the effect of NAG on preimplantation
embryos. This may be due to the fact that the preimplantation embryos were
directly exposed to the ginseng extract in culture, whereas concentrations of
ginseng directly affecting embryos in vivo are unknown due to uncertainties
regarding ginseng compound absorption, metabolism and renal clearance rate
after consumption in the human. It is very likely that oral consumption results in
very little if any embryonic exposure to ginseng compounds in the reproductive
tract. The levels that could accumulate in the reproductive tract for any species
are simply not known.
Studies have determined however, that maximum concentrations of Rb1,
Rg1 and Re in rat plasma after an oral administration of 10 and 300mg/kg of
ginseng powder were between 1.51 to 6.42 ug/ml (Li et al. 2007a). However,
when Shin et al. 2010 attempted to measure Rb1 and Rg1 plasma concentrations
in pregnant mice, no trace of these ginsenosides were found following oral
treatment with an extremely high dose of 2000mg/kg/day of Red Korean ginseng
after 30 min and 2h. Whether these results are transferable to humans, and intact
ginsenosides are absorbed by the gastrointestinal tract and reach the systemic
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circulation before first being metabolized is unknown. These results indicate that
ginsenoside pharmacokinetics is poorly understood in general. The
pharmacokinetics of ginseng extracts and placental transfer of ginsenosides in
humans must be investigated further, but short half-life, poor absorption and rapid
clearance may all contribute to very low exposure levels in the reproductive tract
and could provide reasonable understanding as to why ginseng treatments differ
so much with regards to effects to early development when comparing in vitro
and in vivo treatment regimes.
Overall the results support a cautionary approach to determining whether
ginseng extract consumption has a negative influence on pregnancy and postpartum development. Treatment with 50 mg/kg of NAG ginseng extract does not
negatively affect pregnancy and post-partum development in the mouse.
However, 500 mg/kg/day, certainly has an influence on litter size, and
independent treatment with the ALC extract increases gestation period and pup
growth when compared to the sham group. While my results with high levels of
NAG do not agree with the outcomes from experiments using Korean Red
ginseng, both studies did not observe a negative impact from administration of
low levels of ginseng on pregnancy and post-partum development. While different
experimental designs could be attempted, such as gavaging females before
pregnancy only or throughout gestation only, and more experimental replicates
could be added in order to increase the overall power of the study, it can be
cautiously concluded that it is unlikely that oral consumption of ginseng at typical
daily levels would negatively affect pregnancy and post-partum development in
the mouse
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4.5

Conclusions

In conclusion, my study has revealed the following regarding ginseng
extract effects on preimplantation development in culture and pregnancy and
post-partum development in the mouse.
1. Treatment with either AQ or ALC NAG extracts results in a concentration
dependent blockade of preimplantation development in vitro.
2. Treatment with 1000 ug/ml ALC extract does not negatively affect
preimplantation development in vitro.
3. Preimplantation embryos treated with ALC extract are more likely to
recover from treatment than embryos treated with AQ extract however,
overall recovery from treatment is low for almost all treatments.
4. Treatment with Rg1, Rb1, Re and PSF alone does not replicate the effect
of treatment with full AQ or ALC extract on preimplantation development.
5. Oral administration of 50 mg/kg/day AQ or ALC extract does not affect
gestation, litter size, sex ratio or post-partum growth in the mouse.
6. Oral administration of 500 mg/kg/day AQ or ALC extract does affect
gestation period and pup growth rate.
7. It is likely that oral consumption of typical daily levels of ginseng will not
adversely affect pregnancy and post-partum development, which is
probably due to a very low ginseng accumulation in the reproductive tract
and thus low embryonic exposure to ginseng extract in vivo.
8. Future experiments should be directed towards determining ginseng
extract metabolism, clearance rate and reproductive tract levels.
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9. The mechanisms underlying the effects of ginseng treatment on
preimplantation development in vitro should be investigated.

115
References

Akao, T., M. Kanaoka et al. (1998) Appearance of compound K, a major metabolite
of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration—
measurement of compound K by enzyme immunoassay. Biol Pharm Bull. 21: 245–
249
Albrecht, E. D., G. J. Pepe (1990) Placental steroid hormone biosynthesis in primate
pregnancy. Endocrine Rev. 11: 124-150
Amarante-Paffaro, A., G. S. Queiroz et al. (2004) Phagocytosis as a potential
mechanism for microbial defense of mouse placental trophoblast cells.
Reproduction. 128: 207–18
Angelova, N., H. W. Kong et al. (2008) Recent methodology in phytochemical
analysis of ginseng. Phytochemical Analysis. 19: 2-16
Astrup, A. and N. Finer (2000) Redefining type 2 diabetes “diabesity” or “obesity
dependant diabetes mellitus”. Obes. Rev. 1: 57-59
Attele A. S., J. A. Wu et al. (1999) Ginseng Pharmacology: Multiple constituents and
multiple actions. Biomedical Pharmacology. 58(11): 1685-93
Azike, C. G., P. A. Charpentier et al. (2n011) The Yin and Yang actions of North
American ginseng root in modulating the immune function of macrophages. Chinese
Medicine 6: 21
Benishin C. G. (1992) Actions of ginsenoside Rb1 on choline uptake in central
cholinergic nerve endings. Neurochem Int. 21: 1-5
Benishin, C. G., R. Lee et al., (1992) Effects of ginsenoside Rb1 on the central
cholinergic metabolism. Pharmacology. 42: 223-229
Bent, S. and R. Ko (2004) Commonly used herbal medicines in the United States: a
review. The American journal of medicine. 116(7): 478-85
Brevoort, P. (1998) The booming US botanical market: a new overview. Herbalgram. 44: 33 – 48.
Csapo, A. I. (1956) Progesterone “block”. Am J Anatomy. 98: 273-292
Challis, J. R. G. and D. M. Olsen (1988) Parturition in Knobil E, Neil J (eds): The
Physiology of Reproduction. New York, Ny, Raven Press. 2177-2216

116
Chan, L. Y., P. Y. Chiu et al. (2003) An in-vitro study of ginsenoside Rb1 inducted
teratogenicity using a whole rat embryo culture model. Human Reproduction. 18:
2166-8
Chan, L.Y., P. Y. Chiu et al. (2004) Embryotoxicity study of ginsenoside Rc and Re
in the in vitro rat whole embryo culture. Reproductive Toxicology. 19: 131-134
Chazaud, C., Y. Yamanaka et al. (2006) Early lineage segregation between epiblast
and primitive endoderm in mouse blastocysts through the Grb2-MAPK pathway. Dev
Cell. 10: 615–24
Chen, T. Y. K., J. C. N. Chan et al. (1993) Chinese herbal medicines revisited: a
Hong Kong perspective. Lancet. 342: 1532–1534.
Chin, R.K. (1991) Ginseng and common pregnancy disorders. Asia Oceania J.
Obstet. Gynecol. 17: 379-80
Chu, S. F. and J. T. Zhang (2009) New achievements in ginseng research and its
future prospects. Chin J Integr Med. 15(6): 403-408
Cross, J. C., Z. Werb et al. (1994) Implantation and the placenta: key pieces of the
development puzzle. Science. 266: 1508-151
Cui, J. F., I. Bjorkhem et al. (1997) Gas Chromatographic-mass spectrometric
determination of 20(S)-protopanaxadiol and 20(S)- protopanaxatriol for study on
human urinary excretion of ginsenosides after ingestion of ginseng preparations. J
Chromatogr B Biomed Sci Appl. 689(2): 349-55
De Smet, P. A. (2004) Health risks of herbal remedies: An update. Clinical
Pharmacology & Therapeutics. 76: 1-7
Duda, R. B., S. S. Kang et al. (2001) American ginseng transcriptionally activated
p21 mRNA in breast cancer cell lines. J. Korean Med Sci. 16: S54-S60
Duda R. B., Y. Zhong et al. (1999) American ginseng and breast cancertherapeutic
agents synergistically inhibit MCF-7 breast cancer cell growth. J. Surg. Oncol. 72:
230-239
Eisenberg, D., R. B. David et al. (1998) Trends in alternative medicine use in the
United States. JAMA. 280: 1569 – 1575
Enders, A.C. and C. Schlafke (1968) Cytological aspects of trophoblast- uterine
interaction in early implantation. Am J Anat. 125: 1-30
Ernst, E (1999) Second thoughts about safety of St John's wort. Lancet. 354: 2014-6
Ernst, E (2002) Herbal medicinal products during pregnancy: are they safe? BJOG.

117
109: 227-35
Ernst, E. and A. R. White (2000) The BBC survey of complementary medicine use in
the UK. Complement Ther Med. 8: 32 – 36
Feinberg, R. F., L. C. Kao et al. (1989) Plasminogen activator inhibitor types 1 and 2
in human trophoblasts: PAI-1 is an immunocytochemical marker of invading
trophoblasts. Lab Invest. 61: 20-26
Foster, D.F., R. S. Phillips et al. (2000) Alternative medicine use in older Americans.
J Am Geriatr Soc. 48: 1560-5
Friedberg, E. C. (1986) Cancer biology. (pp. 138-148) W. Freeman and company,
New York
Fu, Y. and L. L. Ji (2003) Chronic ginseng consumption attenuates age-associated
oxidative stress in rats. J. Nutr. 133: 3603-9
Fujimori, T. (2010) Preimplantation development of mouse: A view from Cellular
Behavior. Development, Growth and Differentiation. 52: 253-262
Fujimoto, J., H. Sakaguchi et al. (2001) Inhibitory effect of ginsenoside-Rb2 on
invasiveness of uterine enfometrial cancer cells to the basement membrane. Eur J.
Gynaecol. Oncol. 22: 339-341
Fukushima, S. H., H. Wanibuchi et al. (2001) Inhibition by ginseng of colon
carcinogenesis in rats. J. Korean Med. Sci. S75-S80
Fuzzati, N. (2004) Analysis methods of ginsenosides. J Chromatogr B Analyt
Technol Biomed Life Sci. 812:119-33
Fuzzati, N., B. Gabetta et al. (2000) Determination of ginsenosides in Panax ginseng
roots by liquid chromatography with evaporative light-scattering detection. J AOAC
Int. 83(4): 820-9.
Garfield, R. E., M. S. Kannan et al. (1980) Gap junction formation in myometrium:
control by estrogen, progesterone and prostaglandins. Am J Physiol. 238: C81-C89
Garvey, G. J., G. Hahn et al. (2001) Heavy metal hazards of traditional remedies.
International Journal of Environmental Health Research. 11: 63-71
Gibson, P. S., R. Powrie et al. (2001) Herbal and alternative medicine use during
pregnancy: a cross sectional survey. Obstet Gynecol. 97: S44 – S45
Gilbert, S. F. (2000) Developmental biology, sixth edition. Sunderland, MA, Sinauer
Associates Inc. p. 379-543

118
Goldman, P. (2001) Herbal Medicines Today and the Roots of Modern
Pharmacology. Academia and Clinic. 135(8): 594-600
Gorey, J.D., M. L. Wahlqvist et al. (1992) Adverse reaction to a Chinese herbal
remedy. Med. J. Aust. 157: 484–486
Graham, C. H. and P. K. Lala (1991) Mechanism of control of trophoblast invasion in
situ. J Cell Physiol. 148: 228-234
Hall, B. K. (1998) Germ layers and the germ-layer theory revisited: primary and
secondary germ layers, neural crest as a fourth germ layer, homology, and demise
of the germ-layer theory. Evolutionary Biology. 30: 121–186.
Hall, B. K. (1999) The Neural Crest in Development and Evolution. Springer-Verlag,
New York.
Hall, B. K. (2000). The neural crest as a fourth germ layer and vertebrates as
quadroblastic and not triploblastic. Evolution and Development. 2: 3–5
Hamilton, G. S., J. J. Lysiak et al. (1998) Autocrine-paracrine regulation of human
trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding
protein-1 (IFGBP-1). Exp Cell Res. 244: 147-156
Han, B. H., M. H. Park et al. (1982) Degradation of ginseng saponins under mild
acidic conditions. Planta Med. 44: 146-149
Han, M. and X-L. Fang (2006) Difference in oral absorption of ginsenoside Rg1
between in vitro and in vivo models. Acta Pharmacol Sin. 27(4): 499-05
Harkey, M. R., G. L. Henderson et al. (2001) Variability in commercial ginseng
products: An analysis of 25 products. Am J Clin Nutr. 73: 1101-06
Harvey, A. J., K. L. Kind et al. (2002) REDOX regulation of early embryos
development. Reproduction. 123: 479-86
Hasegawa, H., J-H. Sung et al. (1996) Main ginseng metabolites formed by intestinal
bacteria. Planta Med. 63: 453-455
Hemberger, M. (2012) Health during pregnancy and beyond: Fetal trophoblast cells
as chief co-ordinators of intrauterine growth and reproductive success. Ann Med.
Early online: 1-13
Hirst, J.J., R. Chibbar et al. (1993) Role of oxytocin in the regulation of uterine
activity during pregnancy and in initiation of labor. Semin Reprod Endocrinol. 11:
219-233

119
Hirst, J. J., G. J. Haluska et al. (1991) Comparison of plasma oxytocin and
catecholamine concentrations with uterine activity in pregnant rhesus monekys. J
Clin Endocrinol Metab. 73: 804-810
Houghton, F. D., J. G. Thompson et al. (1996) Oxygen consumption and energy
metabolism of the early mouse embryo. Molecular Reproduction and Development.
44:476-85
Hu, C. and D. D. Kitts (2001) Free Radical Scavenging Capacity as Related to
Antioxidant Activity and Ginsenoside Composition of Asian and North American
Ginseng Extracts. JAOCS. 78(3): 249-55
Ji, Z. N., T. T. Dong et al. (2006) Ginsenoside Re attenuate beta-amyloid and serumfree induced neurotoxicity in PC12 cells. J Ethnopharmacol. 107: 48-52
Johne, A., J. Brockmöller et al. (1999) Pharmacokinetic interaction of digoxin with an
herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 66:
338-45
Johnson, M. H. and J. M McConnell (2004) Lineage allocation and cell polarity
during mouse embryogenesis. Semin Cell Dev Biol. 15(5): 583-97
Joubert, P. H., L. Mathibe (1989) Acute poisoning in developing countries. Adverse
Drug React. Acute Poisoning Rev. 8: 165–178.
Kang, K. S., N. Yamabe et al. (2007) Increase in the free radical scavenging
activities of American ginseng by heat processing and its safety evaluation. Journal
of Ethnopharmacology. 113: 225–232
Kearns, M., and P. K. Lala (1983) Life history of decidual cells: a review. Am J
Reprod Immunol. 3: 78-82
Keirse, M. J. N. C. (1990) Eicosanoids in human pregnancy and parturition, in
Mitchell, M. D. (1991) Eicosanoids in Reproduction. Boca Raton, FL, CRC Press.
199-222
Kim, H. S., E. H. Lee et al. (2004) Effects of ginsenosides Rg3 and Rh2 on the
proliferation of prostate cancer cells. Arch. Pharm. Res. 27: 429-435
Kim, J. J., R. C. Jaffe et al. (1999) Inulin-like growth factor binding protein-1
expression in baboon endometrial stromal cells: regulation by filamentous actin and
requirement for de novo protein synthesis. Endocrinology. 140: 997-1004
Kim, N. D., S. Y. Kang et al. (1994) Ginsenosides evoke endothelium-dependent
vascular relaxation in rat aorta. Gen. Pharmacol. 25: 1071-77

120
Kim, W. Y., J. M. Kim et al. (2000) Steaming of ginseng at high temperatures
enhances biological activity. J. Nat Prod. 63(12): 1702-04
Kimura, I., N. Nakashima et al. (1999) The antihyperglycaemic blend effect of
traditional chinede medicine byakko-ka-ninjiin-to on alloxan and diabetic KK-Cay
mice. J. Pharmacobiodyn. 4: 907-915
Kimura, T., P. A. Saunders et al. (1994) Interactions of ginsenosides with ligandbindings of GABAa and GABAb receptors. Gen Pharmacol. 25: 193-199
Kliman, H. J. (1994) Trophoblast infiltration. Reprod Med Rev. 3: 137-157
Kliman, H. J. (1999) Trophoblast to human placenta. Knobil E Neill JD eds.
Encyclopedia of Reproduction, 4: 834-846 Academic Press, San Diego
Kliman, H. J. (2000) Uteroplacental blood flow. The story of decidualization,
menstruation, and trophoblast invasion. Am J Pathol. 157: 1759-1768
Ko, R. J. (1998). Adulterants in Asian patent medicines. N Engl J Med. 339: 847
Kuo, S. C., C. M. Teng et al. (1990) Antiplatelet components in panax ginseng.
Planta. Med. 56: 164-167
Lee, F. C. (1992) Facts about ginseng, the elixir of life. Hollyn International Corp.,
Elizabeth, NJ
Lee, K. S. (1980) Effects of saponins on the vascular smooth muscle. Proceedings of
3rd Internation Ginseng Symposium. Pp. 71-76
Lee, J. H., G. N. Chen et al. (2006) Preparation of black ginseng and its antitumor
activity. Korean Journal of Oriental Physiology and Pathology. 20: 951-956
Lee, S. R., M. R. Kim et al. (2008) Effects of ginsenosides on organogenesis and
expression of glutathione peroxidase genes in cultured rat embryos. Journal of
Reproduction and Development. 54:164-170
Lee, S. R., M. R. Kim et al. (2009) Black ginseng inhibits ethanol-induced
teratogenesis in cultured mouse embryos through its effects on antioxidant activity.
Toxicology in Vitro. 23: 47-52
Li, X., J. Sun et al. (2007a) Simultaneous determination of panax notoginsenoside
R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ ESI/MS: platform for
the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of
multiple constituent traditional Chinese medicine. Biomedical Chromatography. 21:
735-46

121
Li, X., G. Wang et al. (2007b) Pharmacokinetic and absolute bioavailability study of
total panax notoginsenoside, a typical multiple constituent traditional chinese
medicine (TCM) in rats. Biol Pharm Bull. 30: 847-51
Liberti L. E. and A. Der Marderosian (1978). Evaluation of commercial ginseng
products. J Pharmaceut Sci. 67:1487–1489
Lin, S. P., R. K. K. Lee at al. (2001) In vivo hatching phenomenon of mouse
blastocysts during preimplantation development. Journal of assisted reproduction
and genetics. 18(6): 341-345
Lim, J. H., T. C. Wen et al. (1997) Protection of ischemic hippocampal neurons by
ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res. 28: 191-200
Liu, P., Y. Xu et al. (2005a) Developmental toxicity research of ginsenoside Rb1
using a whole mouse embryo culture model. Birth Defects Research. 74: 207-209
Liu, P., Y. Xu et al. (2005b) Effects of ginsenoside Rb1 on mouse embryonic
development in vitro. J Hygiene Res. 34:175–177
Liu, P., H. Yin et al. (2006) Effects of ginsenoside Rg1 on postimplantation rat and
mouse embryos cultured in vitro. Toxicol In Vitro. 20: 234–238
Lü, J. M., Q. Yao et al. (2009) Ginseng compounds: an update on their molecular
mechanisms and medical applications. Curr Vasc Pharmacol. 7(3): 293-302
Lye, S. J. and J. R. G. Challis (1989) Paracrine and endocrine control of myometrial
activity, in Gluckman, P.D., B. M. Johnston et al., (1989) Advances in petal
physiology: Reviews in Honor of GC Liggins. Research in Perinatal Medicine (VIII).
Ithica, NY, Perinatology Press. 361-375
MacLennan, A. H., D. H. Wilson et al. (1996) Prevalence and cost of alter- native
medicine in Australia. Lancet. 347: 569 – 573
Marcus, D. M. and A. P. Grollman (2002) Botanical medicines—the need for new
regulations. N Engl J Med. 347: 2073–2076
McGeady, T. A., P. J. Quinn et al. (2006) Gastrulation. In: Veterinary embryology.
Blackwell Publishing Ltd. p.34–41.
Mills, E., R. Singh et al. (2003). Sale of kava extract in some health food stores.
CMAJ 169: 1158–1159
Mochizuki, M., Y. C. Yoo (1995) Inhibitory effect of tumor metastasis in mice by
saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol.
Pharm. Bull. 18: 1197-1202

122
Nakata, H., Y. Kikuchi et al. (1998) Inhibitory effects of ginsenoside Rh2 on tumor
growth in nude mice bearing human ovarian cancer cells. J. Cancer Res. 89: 733740
Nathanielsz, P. W. and M. B. O. M. Honnebier (1992) Myometrial function, in Drife, J.
O. and A. A. Calder (1992) Prostaglandins and the uterus. London, Springer-Verlag.
161-176
Odashima, S., T. Ota et al. (1989) Of Phenotypic reverse transformation by plant
glycosides in cultured cancer. Gan to Kagaku Ryoho. 16: 1483-89
Olson, D. M., J. E. Mijovic et al. (1995) Control of human parturition. Seminars in
perinatology. 19(1): 52-63
Ong, C.O., L. Y. Chan et al. (2005) Use of traditional Chinese herbal medicine during
pregnancy: a prospec- tive survey. Acta Obstetricia et Gynecologica Scandinavica.
84(7): 699–700.
O’Rahilly, R. and F. Müller (1999) Summary of the initial development of the human
nervous system. Teratology. 60: 39–41
Parast, M. M., S. Aeder et al. (2001) Trophoblast giant-cell differentiation involves
changes in cytoskeleton and cell motility. Dev Biol. 230: 43-60
Park, J. D., D. K. Rhee et al. (2005) Biological activities and chemistry of saponins
from panax ginseng C.A. Meyer. Phytochemistry Reviews. 4: 159-175
Perry, E. K. (1986) The cholinergic hypothesis-ten years on. Br Med Bull. 42: 63-69
Rossant, J. and J. C. Cross (2001) Placental development: lessons from mouse
mutants. Nat Rev Genet. 2: 538-48
Ruschitzka, F., P. J. Meier et al. (2000) Acute heart transplant rejection due to Saint
John's wort. Lancet. 355: 548-9
Saito, H., M. Tsuchiya et al. (1977) Effect of panax ginseng root on conditioned
avoidance response in rats. Jpn J Pharmacol. 27: 509-516
Salim, K. N., B. S. McEwen et al. (1997) Ginsenosides Rb1 regulates ChAT, NGF
and trkA mRNA expression in the rat brain. Brain Res Mol Brain Res. 47: 177-182
Schultz, R. M. (2002) The molecular foundations of the maternal to zygotic transition
in the preimplantation embryo. Human Reproduction. (8)4: 323-31
Senger, P. L. (2003) Embryogenesis of the pituitary gland and the male or female
reproductive system. In: Pathways to pregnancy and parturition. Current

123
Conceptions Inc. p. 80–101
Shi, Q., Q. Hao et al. (2005) Ginsenoside-Rd from panax notoginseng enhances
astrocyte differentiation from neural stem cells. Life Sci. 76: 983-95
Shin, S., J. Y. Jang, et al. (2010) Korean Red Ginseng Extract does not cause
embryo-fetal death or abnormalities in mice. Birth Defects Research. 89: 78-85
Shirayoshi, Y., T. S. Okada et al. (1983) The calcium-dependant cell-cell adhesion
system regulates inner cell mass formation and sell surface polarization in early
mouse development. Cell. 35: 631-638
Sievenpiper J. L., J. T. Arnason et al. (2003) Null and opposing effects of Asian
ginseng (Panax ginseng C.A. Meyer) on acute glycemia: results of two acute dose
escalation studies. J Am Coll Nutr . 22: 524–532
Simon, C., A. Frances et al. (1994) Interleukin-1 system in the materno-trophoblast
unit in human implantation: Immunohistochemical evidence for autocrine/paracrine
function. J Clin Endocrinol Metab. 78: 847-54
Simon, C., A. Mercader et al. (1997) The interleukin-1 system and human
implantation. Am J Reprod Immunol. 37: 64-72
Song, G. Y., H. J. Oh et al. (2006) Effect of black ginseng on body weight and lipid
profiles in male rats fed normal diets. Korean Journal of Pharmacognosy. 50: 381385
Sonnenborn, U., and Y. Proppert (1990) Ginseng (Panax ginseng C.A. Meyer).
Zeitschrift fur phytotherapie. 11: 35-49
Standish, L. J., K. B. Greene et al. (2001) Alternative medicine use in HIV-positive
men and women: demographics, utilization patterns and health status. AIDS
Care.13: 197–208
Stein, C. M. (2002). Are herbal products dietary supplements or drugs? An important
question for public safety. Clin Pharmacol Ther. 71: 411–413
Strickland, S. and W. G. Richards (1992) Invasion of the trophoblasts. Cell. 71: 355357
Sutherland, A. (2003) Mechanisms of implantation in the mouse: differentiation and
functional importance of trophoblast giant cell behavior. Dev Biol. 258: 241-51
Takemoto, Y., T. Ueyama et al. (1984) Potentiation of nerve growth factors-mediated
nerve fibre production in organ cultures of chicken embryonic ganglia by ginseng
saponins: Structure-activity relationships. Chem Pharm Bull (Tokyo). 32: 3128-33

124
Tarantino, S., H. G. Verhage et al. (1992) Regulation of insulin-like growth factor
binding proteins in the baboon (Papio Anubis) uterus during early pregnancy.
Endocrinology. 130: 2354-2362
Tawab, M. A., U. Bahr, et al. (2003) Degradation of ginsenosides in humans after
oral administration. Drug Metabolism and Disposition. 31: 1065-1071
Taylor, N. F., M. C. Martin et al. (1983) The fetus determines circadian oscillation of
myometrial electromyographic activity in the pregnant rhesus monkey. Am J Ostet
Gynecol. 146: 557-567
Teng, C. M., S. C. Kuo et al., (1989) Antiplatelet actions of panaxynol and
ginsenosides isolated from ginseng. Biochim. Biophys. Act. 990: 315-320
Tode, T., Y. Kikuchi et al. (1993) Inhibitory effects of oral administration of
ginsenoside Rh2 on tumor growth in nude mice bearing serious cyst
adenocarcinoma of the human ovary. Nippon Sanka Fukinka Gakkai Zasschi. 45:
1275-82
Tsang, D., H. W. Yeung et al. (1985) Ginseng saponins: Influence on
neurotransmitter uptake in rat brain synaptosomes. Planta Med. 3: 221-224
Vuksan, V., J. L. Sievenpiper et al. (2000) American ginseng (Panax quinquefolius
L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2
diabetes mellitus. Arch. Intern. Med. 160: 1009-13
Wargovich, M. J. (2001) Colon cancer chemoprevention with ginseng and other
botanicals. Journal of Korean Medical Science. 16: S81–86

Watson, A. J. and L.C. Barcroft (2001) Regulation of blastocyst formation. Front
Biosci. 6: 708–730

Wen, T. C., H. Yoshimura et al. (1996) Ginseng root prevents learning
disability and neuronal loss in gerbils with 5-minute forebrain ischemia. Acta
neuropathol. 91: 15-22
Wood, M. J., R. L. Stewart et al. (2003) Use of complementary and alternative
medical therapies in patients with cardiovascular disease. Am Heart J.145: 806–12
Wu, X. G., D. H. Zhu et al. (2001) Anticarcinogenic effect of red ginseng on the
development of liver cancer induced by diethylnitrosamine in rats. J. Korean Med.
16: S61-S65

125
Xie, J. T., Z. H. Shao et al. (2006) Antioxidant effects of ginsenoside Re in
cardiomyocytes. Eur J Pharmacol. 532:
532 201-7
Yamaguchi, Y., K Haruta et al. (1995) Effects of ginsenosides on impaired
performance induced in rat by scopolamine in a radial-arm maze.
Psychoneuroendocrinology. 20: 645-53
Yamaguchi, Y., M. Higashi et al. (1996) Effects of oral and intraventricular
administration of ginsenoside Rg1 on the performance impaired by scopolamine in
rats. Biomed Res. 17: 487-90
Yammamoto, M. (1992) Effects of administration of red ginseng on hypertension,
normotension and hypotension. Ginseng Rev. 9: 15-20
Yue, Q. Y., C. Bergquist et al. (2000) Safety of St John's wort (Hypericum
perforatum). Lancet. 355: 576-7
Yun, T. K. (2003) Experimental and epidemiological evidence on non-organ specific
cancer preventive effect of Korean ginseng and identification of active compounds.
Mutation Research. 523-524: 63-74
Yun, T. K., T. S. Yun et al. (1983) Anticarcinogenic effect of long-term oral
administration of red ginseng on new born mice exposed to various chemical
carcinogens. Cancer Detect. Prev. 6: 515-525
Zhang, H., Q. M. Zhou et al. (2006) Ginsenoside R (e) increases fertile and
asthenozoospermic infertile human sperm motility by induction of nitric oxide
synthase. Archives of Pharmacol Research. 29(2): 145-151
Zhong, G. and Y. Jiang (1997) Calcium channel blockage of anti-free radical actions
of ginsenosides. Chin Med J (Engl).110: 28-29

126

Curriculum Vitae

Danyka Belanger
Children’s Health Research Institute
Victoria Research Labs, A-5-148
800 Commissioners Rd, E
London Ontario N6C 2V5
FORMAL EDUCATION
Master of Science – Physiology
The University of Western Ontario
London, Ontario, Canada

2010-2012

Bachelors Degree – Honours Health Sciences
University of Ottawa
Ottawa, Ontario, Canada

2005-2009

HONOURS AND AWARDS
CIHR Training Program in Reproduction, Early
Development, and the Impact of Health Scholarship
Canadian Institutes for Health Research

2010-2012

Western Graduate Research Scholarship (WGRS)
The University of Western Ontario
London, Ontario, Canada

2010-2012

Dean’s Honour List
University of Ottawa
Ottawa, Ontario, Canada

2005-2009

Entrance Scholarship
University of Ottawa
Ottawa, Ontario, Canada

2005-2006

RELATED WORK EXPERIENCE

127
Clerk
Ottawa Hospital
Ottawa, Ontario, Canada

2009-2010

ORAL PRESENTATIONS
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2012) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro, and
pregnancy and Post-Partum Development in the Mouse. London Health
Research Day, London ON, CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2011) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro, and
pregnancy and Post-Partum Development in the Mouse. Ontario Ginseng
Innovation and Research Consortium (OGIRC) trainee day, UWO, London ON,
CAN

POSTER PRESENTATIONS
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2012) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro, and
pregnancy and Post-Partum Development in the Mouse. Paul Harding
Research Day, London On, CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2011) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro, and
pregnancy and Post-Partum Development in the Mouse. Ontario Ginseng
Innovation and Research Consortium (OGIRC) trainee day, UWO, London ON,
CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2011) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro. CIHR
Training Program in Reproduction, Early Development, and the Impact of Health,
Ottawa ON, CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2011) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro. Paul Harding
Research Day, UWO, London ON, CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2011) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro. Margaret
Moffat Research Day, Lawson Research Day, UWO, London On, CAN
Belanger D., Feyles V., Gianetto-Berruti A., Watson A.J. (2010) Ginseng Extract
Treatment Influences on Preimplantation Development In Vitro. CIHR

128
Training Program in Reproduction, Early Development, and the Impact of Health,
Ottawa ON, CAN

